LennartM personal page - To The Moon

LennartM

LennartM

No personal profile

676Follow

69Followers

1Topic

0Badge

2025-11-20

🤩👏🏻

SEALSQ Enters Partnership With BWT Alpine Formula One Team

2025-11-18

going up

Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results

2025-11-18

🚀❤️

Iterum Therapeutics Q3 Adjusted EPS USD -0.16

2025-11-18

LAES buy and hold wait till Nov 21 👏🏻🥳🚀

Mixed options sentiment in Sealsq Corp with shares down 8.13%

2025-11-14

$SEALSQ Corp(LAES)$

2025-11-07

up

WISeKey, Sealsq provide update on Swiss Armed Forces collaboration

2025-11-05

BUY

Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)

2025-10-31

👌🏻🥳

SEALSQ and IC’Alps Unify Expertise to Deliver Integrated Post-Quantum Cybersecurity and Functional Safety for Autonomous Vehicles

2025-10-31

Share your opinion about this news…

Stock Track | SEALSQ Corp Soars 5.49% Pre-market on Strategic Partnership for Satellite Launch Services

2025-07-10

$Iterum Therapeutics Plc(ITRM)$ 🎸🚀🙌🏼🎁🎰

2024-10-23

$Tiger Brokers(TIGR)$ 🙏🏻🚀🚀🚀🧨

2024-10-15

$NVIDIA Corp(NVDA)$ 👋🏻🙏🏻

2023-09-01

$Snap Inc(SNAP)$ 🍻🍻🍻🎉🙏🏻

2022-02-16

like pls

Nio Stock Should Trade Sideways as Its Earnings Period Approaches

2022-02-10

like pls

Want 140% to 225% Gains? 2 Growth Stocks to Buy, According to Wall Street

2022-02-08

like pls

Sorry, the original content has been removed

2022-02-07

like pls

Some Blockchain Stocks Soared in Morning Trading

2022-02-06

like pls

3 No-Brainer Stocks to Buy With $1,000 Right Now

2022-01-30

pls like

EV Stocks Dropped in Morning Trading

2022-01-30

please like

Goldman Sachs Predicts Fed Will Raise Rates Five Times This Year

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3576017931077934","uuid":"3576017931077934","gmtCreate":1612924005899,"gmtModify":1639173341937,"name":"LennartM","pinyin":"lennartm","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":69,"headSize":676,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.19","exceedPercentage":"80.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.09","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":502288106369792,"gmtCreate":1763647591241,"gmtModify":1763647594688,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"🤩👏🏻","listText":"🤩👏🏻","text":"🤩👏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/502288106369792","repostId":"2584132712","repostType":2,"repost":{"id":"2584132712","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1763646868,"share":"https://ttm.financial/m/news/2584132712?lang=en_US&edition=fundamental","pubTime":"2025-11-20 21:54","market":"sh","language":"en","title":"SEALSQ Enters Partnership With BWT Alpine Formula One Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2584132712","media":"MT Newswires Live","summary":"SEALSQ  and BWT Alpine Formula One Team said Thursday that they have entered into a partnership to explore the application of quantum-related technologies across BWT Alpine Formula One Team's operation and security systems.Financial details of the partnership were not provided.Shares of SEALSQ were up over 6% in recent Thursday premarket activity.","content":"<html><body><p> SEALSQ (LAES) and BWT Alpine Formula One Team said Thursday that they have entered into a partnership to explore the application of quantum-related technologies across BWT Alpine Formula One Team's operation and security systems.</p><p>Financial details of the partnership were not provided.</p><p>Shares of SEALSQ were up over 6% in recent Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEALSQ Enters Partnership With BWT Alpine Formula One Team</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEALSQ Enters Partnership With BWT Alpine Formula One Team\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-20 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SEALSQ (LAES) and BWT Alpine Formula One Team said Thursday that they have entered into a partnership to explore the application of quantum-related technologies across BWT Alpine Formula One Team's operation and security systems.</p><p>Financial details of the partnership were not provided.</p><p>Shares of SEALSQ were up over 6% in recent Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LAES":"SEALSQ Corp","TISI":"Team Inc","BK4120":"环境与设施服务","BK4141":"半导体产品"},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2584132712","content_text":"SEALSQ (LAES) and BWT Alpine Formula One Team said Thursday that they have entered into a partnership to explore the application of quantum-related technologies across BWT Alpine Formula One Team's operation and security systems.Financial details of the partnership were not provided.Shares of SEALSQ were up over 6% in recent Thursday premarket activity.","news_type":1,"symbols_score_info":{"LAES":1,"TISI":1.5}},"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":501513158075128,"gmtCreate":1763449373597,"gmtModify":1763449377437,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"going up","listText":"going up","text":"going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/501513158075128","repostId":"2583038815","repostType":2,"repost":{"id":"2583038815","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1763121600,"share":"https://ttm.financial/m/news/2583038815?lang=en_US&edition=fundamental","pubTime":"2025-11-14 20:00","market":"nz","language":"en","title":"Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583038815","media":"Dow Jones","summary":"--Commercially Launched ORLYNVAH in the United States in August 2025--. DUBLIN, Ireland and CHICAGO, Nov. 14, 2025  -- Iterum Therapeutics plc  , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025.\"We are thrilled to have launched ORLYNVAH in the United States in August 2025 for the treatment of uncomplicated urinary tract infections ,\" said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. \"The significance of this milestone cannot be overstated--particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we an","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     --Commercially Launched ORLYNVAH<a href=\"https://laohu8.com/S/TM\">$(TM)$</a> in the United States in August 2025-- \n</p>\n<p>\n     --Extended Cash Runway into Q2 2026-- \n</p>\n<p>\n     --Company to host conference call today at 8:30amET-- \n</p>\n<p>\n     DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. \n</p>\n<p>\n     \"We are thrilled to have launched ORLYNVAH(TM) in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),\" said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. \"The significance of this milestone cannot be overstated--particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we anticipate modest sales in 2025. Looking ahead to 2026, as we continue to build momentum, we currently expect net product sales of ORLYNVAH(TM) to range between $5 million and $15 million, depending on uptake and payer coverage. We will continue to refine our guidance as market dynamics evolve over the next few quarters.\" \n</p>\n<p>\n     Highlights and Recent Events \n</p>\n<pre style=\"white-space: pre\">\n   -- Launch of ORLYNVAH(TM) for uUTIs in August 2025: Iterum commercially \n      launched ORLYNVAH(TM) in the United States. with its commercialization \n      partner, EVERSANA Life Science Services, LLC (EVERSANA), in August 2025. \n \n   -- Expansion of Patent Estate: Iterum has been granted a patent in China as \n      patent number ZL202180020106.6, entitled \"Combinations of Beta-Lactam \n      Compounds, Probenecid, and Valproic Acid and Uses Thereof\", that covers a \n      combination of sulopenem etzadroxil, probenecid, and valproic acid for \n      treating specified diseases. This Chinese patent is projected to expire \n      in March 2041, absent any patent term extensions, and assuming timely \n      payments of all maintenance fees during the lifetime of the patent. In \n      addition, Iterum has been granted a patent in Mexico as patent number \n      426995, entitled \"Combinations of Beta-Lactam Compounds and Probenecid \n      and Uses Thereof\", that covers a bilayer tablet comprising sulopenem \n      etzadroxil and probenecid, methods of preparing the bilayer tablet, and \n      the bilayer tablet for use in treating specified diseases. This Mexican \n      patent is projected to expire in December 2039, absent any patent term \n      extensions, and assuming timely payments of all maintenance fees during \n      the lifetime of the patent. \n \n   -- Presented at IDWeek: Iterum presented two posters at the Infectious \n      Disease Society of America's IDWeek 2025 conference in October 2025 and \n      conducted a Learning Lounge at IDWeek titled 'An Overview of Urinary \n      Tract Infection in Adult Women: Focus on Oral Sulopenem.' \n</pre>\n<p>\n     Third Quarter 2025 Financial Results \n</p>\n<p>\n     Cash and cash equivalents were $11.0 million as of September 30, 2025. Based on Iterum's current operating plan, Iterum expects that its cash and cash equivalents as of September 30, 2025, together with $2.6 million of net proceeds raised under its at-the-market offering program from October 1, 2025 through November 13, 2025, will be sufficient to fund its operations into the second quarter of 2026. As of November 13, 2025, Iterum had approximately 52.8 million ordinary shares outstanding. \n</p>\n<p>\n     Net product revenues for the third quarter 2025 were $0.4 million related to sales of ORLYNVAH(TM) which launched in August 2025 and included initial stocking at Iterum's specialty pharmacy locations for distribution in its targeted territories. \n</p>\n<p>\n     Cost of sales expense for the third quarter 2025 was $0.02 million and primarily consists of royalty payments pursuant to Iterum's license agreement with Pfizer Inc (Pfizer). Prior to approval in October 2024, costs incurred for the manufacture of ORLYNVAH(TM) were recorded as research and development expenses. \n</p>\n<p>\n     Amortization of intangible asset for the third quarter 2025 was $0.3 million and related to the finite-lived intangible asset recognized in relation to the regulatory milestone payment payable to Pfizer upon approval of ORLYNVAH(TM) by the FDA. \n</p>\n<p>\n     Research and development expenses for the third quarter 2025 were $1.3 million compared to $3.1 million for the same period in 2024. The decrease for the three-month period was primarily due to lower chemistry, manufacturing and control <a href=\"https://laohu8.com/S/CMC\">$(CMC)$</a> related expenses. Following approval, costs incurred for the manufacture of ORLYNVAH(TM) have been capitalized to inventory. \n</p>\n<p>\n     Selling, general and administrative expenses for the third quarter 2025 were $6.5 million compared to $1.8 million for the same period in 2024. The increase for the three-month period was primarily due to the commercialization of ORLYNVAH(TM), which was launched in August 2025. \n</p>\n<p>\n     Adjustments to the fair value of derivatives for the third quarter 2025 was $0.7 million compared to $0.4 million for the same period in 2024. The non-cash adjustment for the third quarter 2025 and 2024 primarily related to an increase in the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the Royalty-Linked Notes) due to the passage of time. \n</p>\n<p>\n     Net loss for the third quarter 2025 was $9.0 million compared to a net loss of $6.1 million for the same period in 2024. Non-GAAP1 net loss for the third quarter 2025 of $7.3 million compared to a non-GAAP(1) net loss of $4.8 million for the same period in 2024. \n</p>\n<p>\n     Conference Call Details \n</p>\n<pre style=\"white-space: pre\">\n   -- Iterum will host a conference call today, Friday, November 14, 2025 at \n      8:30 a.m. Eastern Time. The dial-in information for the call is as \n      follows: United States: 1 833 470 1428; International: 1 404 975 4839; \n      Access code: 459214 \n</pre>\n<p>\n     Non-GAAP Financial Measures \n</p>\n<p>\n     To supplement Iterum's financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), Iterum presents non-GAAP net loss and non-GAAP net loss per share to exclude from reported GAAP net loss and GAAP net loss per share, intangible asset amortization ($0.3 million and $1.0 million); share-based compensation expense ($0.1 million and $0.2 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.0 million and $0.1 million); the non-cash amortization of the Exchangeable Notes ($0.0 million and $0.2 million); the interest expense associated with accrued interest on the promissory note issued to Pfizer ($0.6 million and $1.4 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.7 million and $1.8 million) for the three and nine months ended September 30, 2025, and share-based compensation expense ($0.1 million and $0.3 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.2 million and $0.6 million); the non-cash amortization of the Exchangeable Notes ($0.6 million and $1.7 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.4 million and $1.2 million) for the three and nine months ended September 30, 2024. \n</p>\n<p>\n     Iterum believes that the presentation of non-GAAP net loss and non-GAAP net loss per share, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by investors, analysts, and Iterum's management in assessing Iterum's performance and results from period to period. These non-GAAP financial measures closely align with the way management measures and evaluates Iterum's performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net loss or other financial measures calculated in accordance with GAAP. Non-GAAP net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and represents GAAP net loss, which is the most directly comparable GAAP measure, adjusted to exclude intangible asset amortization; share-based compensation expense; the interest expense associated with accrued interest on the Exchangeable Notes; the non-cash amortization of the Exchangeable Notes; the interest expense associated with accrued interest on the promissory note issued to Pfizer; and the non-cash adjustments to the fair value of the Royalty-Linked Notes for the three and nine months ended September 30, 2025 and September 30, 2024. Because of the non-standardized definitions of non-GAAP financial measures, non-GAAP net loss and non-GAAP net loss per share used by Iterum in this press release and accompanying tables has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconciliation of non-GAAP net loss to GAAP net loss and non-GAAP net loss per share to GAAP net loss per share have been provided in the tables included in this press release. \n</p>\n<p>\n     About Iterum Therapeutics plc \n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its New Drug Application (NDA) for ORLYNVAH(TM) (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com. \n</p>\n<p>\n     About ORLYNVAH(TM) \n</p>\n<p>\n     ORLYNVAH(TM) is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH(TM) possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. \n</p>\n<p>\n     Cautionary Note Regarding Forward-looking Statements \n</p>\n<p>\n     This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including our expectation that ORLYNVAH(TM) 2026 net product sales will be between $5 million and $15 million, the development, therapeutic and market potential of ORLYNVAH(TM) and the sufficiency of Iterum's cash resources to fund its operating expenses into the second quarter of 2026. In some cases, forward-looking statements can be identified by words such as \"may,\" \"believes,\" \"intends,\" \"seeks,\" \"anticipates,\" \"plans,\" \"estimates,\" \"expects,\" \"should,\" \"assumes,\" \"continues,\" \"could,\" \"would,\" \"will,\" \"future,\" \"potential\" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including risks and uncertainties concerning Iterum's ability to raise sufficient capital and successfully implement its commercialization plans for ORLYNVAH(TM) with its commercial partner, EVERSANA, including Iterum's ability to expand and maintain a sales force, the protection provided by Iterum's patents, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing its commercialization of ORLYNVAH(TM), the market opportunity for and the potential market acceptance of ORLYNVAH(TM) for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, uptake of ORLYNVAH(TM) by physicians and payer coverage, existing or new competition for ORLYNVAH(TM), Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption \"Risk Factors\" in its Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. \n</p>\n<p>\n     Investor Contact: \n</p>\n<p>\n     Judy Matthews \n</p>\n<p>\n     Chief Financial Officer 312-778-6073 \n</p>\n<p>\n     IR@iterumtx.com \n</p>\n<p>\n     (1) Definition and reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release \n</p>\n<pre style=\"white-space: pre\">\n \n                        ITERUM THERAPEUTICS PLC \n             Condensed Consolidated Statement of Operations \n             (In thousands except share and per share data) \n                              (Unaudited) \n \n                      Three Months Ended          Nine Months Ended \n                        September 30,               September 30, \n                      2025          2024          2025          2024 \nProduct Revenue, \n net              $       390   $        --   $       390   $        -- \n \nCosts and \nexpenses: \nCost of sales     $       (20)  $        --   $       (20)  $        -- \nAmortization of \n intangible \n asset                   (349)           --        (1,036)           -- \nResearch and \n development           (1,261)       (3,107)       (2,852)       (9,159) \nSelling, general \n and \n administrative        (6,491)       (1,780)      (13,452)       (5,867) \nTotal operating \n expenses              (8,121)       (4,887)      (17,360)      (15,026) \n                   ----------    ----------    ----------    ---------- \nOperating loss         (7,731)       (4,887)      (16,970)      (15,026) \nInterest \n expense, net            (441)         (590)       (1,291)       (1,648) \nAdjustments to \n fair value of \n derivatives             (673)         (433)       (1,807)       (1,226) \nOther expense, \n net                       (2)          (48)          (60)          (77) \nIncome tax \n expense                 (132)         (136)         (251)         (215) \nNet loss          $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share -- basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nWeighted average \n ordinary shares \n outstanding -- \n basic and \n diluted           45,801,927    20,044,270    39,975,269    17,352,918 \n                   ==========    ==========    ==========    ========== \n \nReconciliation \nof non-GAAP net \nloss to GAAP \nnet loss \n--------------- \nNet loss - GAAP   $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \nIntangible asset \n amortization             349            --         1,036            -- \nShare based \n compensation              53            68           170           274 \nInterest expense \n - accrued \n interest and \n amortization on \n Exchangeable \n Notes                     --           756           282         2,255 \nInterest on \n promissory note \n - non-cash               562            --         1,415            -- \nAdjustments to \n fair value of \n derivatives              673           433         1,807         1,226 \nNon-GAAP net \n loss             $    (7,342)  $    (4,837)  $   (15,669)  $   (14,437) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share - basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nNon-GAAP net \n loss per share \n - basic and \n diluted          $     (0.16)  $     (0.24)  $     (0.39)  $     (0.83) \n                   ==========    ==========    ==========    ========== \n \n \n \n                     ITERUM THERAPEUTICS PLC \n            Condensed Consolidated Balance Sheet Data \n                          (In thousands) \n                           (Unaudited) \n \n                                        As of           As of \n                                    September 30,    December 31, \n                                          2025            2024 \nCash, cash equivalents and \n short-term investments             $      11,002    $     24,125 \nAccounts receivable                           448              -- \nInventory                                   1,149              -- \nIntangible asset, net                      18,710          19,746 \nOther assets                                1,194             724 \nTotal assets                        $      32,503    $     44,595 \nPfizer Promissory Note              $      21,215    $     20,300 \nExchangeable notes                             --          14,463 \nRoyalty-linked notes                       12,520          10,771 \nOther liabilities                           6,149           3,142 \nTotal liabilities                          39,884          48,676 \nTotal shareholders' deficit                (7,381)         (4,081) \nTotal liabilities and \n shareholders' deficit              $      32,503    $     44,595 \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2025 07:00 ET (12:00 GMT)\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-14 20:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     --Commercially Launched ORLYNVAH<a href=\"https://laohu8.com/S/TM\">$(TM)$</a> in the United States in August 2025-- \n</p>\n<p>\n     --Extended Cash Runway into Q2 2026-- \n</p>\n<p>\n     --Company to host conference call today at 8:30amET-- \n</p>\n<p>\n     DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. \n</p>\n<p>\n     \"We are thrilled to have launched ORLYNVAH(TM) in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),\" said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. \"The significance of this milestone cannot be overstated--particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we anticipate modest sales in 2025. Looking ahead to 2026, as we continue to build momentum, we currently expect net product sales of ORLYNVAH(TM) to range between $5 million and $15 million, depending on uptake and payer coverage. We will continue to refine our guidance as market dynamics evolve over the next few quarters.\" \n</p>\n<p>\n     Highlights and Recent Events \n</p>\n<pre style=\"white-space: pre\">\n   -- Launch of ORLYNVAH(TM) for uUTIs in August 2025: Iterum commercially \n      launched ORLYNVAH(TM) in the United States. with its commercialization \n      partner, EVERSANA Life Science Services, LLC (EVERSANA), in August 2025. \n \n   -- Expansion of Patent Estate: Iterum has been granted a patent in China as \n      patent number ZL202180020106.6, entitled \"Combinations of Beta-Lactam \n      Compounds, Probenecid, and Valproic Acid and Uses Thereof\", that covers a \n      combination of sulopenem etzadroxil, probenecid, and valproic acid for \n      treating specified diseases. This Chinese patent is projected to expire \n      in March 2041, absent any patent term extensions, and assuming timely \n      payments of all maintenance fees during the lifetime of the patent. In \n      addition, Iterum has been granted a patent in Mexico as patent number \n      426995, entitled \"Combinations of Beta-Lactam Compounds and Probenecid \n      and Uses Thereof\", that covers a bilayer tablet comprising sulopenem \n      etzadroxil and probenecid, methods of preparing the bilayer tablet, and \n      the bilayer tablet for use in treating specified diseases. This Mexican \n      patent is projected to expire in December 2039, absent any patent term \n      extensions, and assuming timely payments of all maintenance fees during \n      the lifetime of the patent. \n \n   -- Presented at IDWeek: Iterum presented two posters at the Infectious \n      Disease Society of America's IDWeek 2025 conference in October 2025 and \n      conducted a Learning Lounge at IDWeek titled 'An Overview of Urinary \n      Tract Infection in Adult Women: Focus on Oral Sulopenem.' \n</pre>\n<p>\n     Third Quarter 2025 Financial Results \n</p>\n<p>\n     Cash and cash equivalents were $11.0 million as of September 30, 2025. Based on Iterum's current operating plan, Iterum expects that its cash and cash equivalents as of September 30, 2025, together with $2.6 million of net proceeds raised under its at-the-market offering program from October 1, 2025 through November 13, 2025, will be sufficient to fund its operations into the second quarter of 2026. As of November 13, 2025, Iterum had approximately 52.8 million ordinary shares outstanding. \n</p>\n<p>\n     Net product revenues for the third quarter 2025 were $0.4 million related to sales of ORLYNVAH(TM) which launched in August 2025 and included initial stocking at Iterum's specialty pharmacy locations for distribution in its targeted territories. \n</p>\n<p>\n     Cost of sales expense for the third quarter 2025 was $0.02 million and primarily consists of royalty payments pursuant to Iterum's license agreement with Pfizer Inc (Pfizer). Prior to approval in October 2024, costs incurred for the manufacture of ORLYNVAH(TM) were recorded as research and development expenses. \n</p>\n<p>\n     Amortization of intangible asset for the third quarter 2025 was $0.3 million and related to the finite-lived intangible asset recognized in relation to the regulatory milestone payment payable to Pfizer upon approval of ORLYNVAH(TM) by the FDA. \n</p>\n<p>\n     Research and development expenses for the third quarter 2025 were $1.3 million compared to $3.1 million for the same period in 2024. The decrease for the three-month period was primarily due to lower chemistry, manufacturing and control <a href=\"https://laohu8.com/S/CMC\">$(CMC)$</a> related expenses. Following approval, costs incurred for the manufacture of ORLYNVAH(TM) have been capitalized to inventory. \n</p>\n<p>\n     Selling, general and administrative expenses for the third quarter 2025 were $6.5 million compared to $1.8 million for the same period in 2024. The increase for the three-month period was primarily due to the commercialization of ORLYNVAH(TM), which was launched in August 2025. \n</p>\n<p>\n     Adjustments to the fair value of derivatives for the third quarter 2025 was $0.7 million compared to $0.4 million for the same period in 2024. The non-cash adjustment for the third quarter 2025 and 2024 primarily related to an increase in the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the Royalty-Linked Notes) due to the passage of time. \n</p>\n<p>\n     Net loss for the third quarter 2025 was $9.0 million compared to a net loss of $6.1 million for the same period in 2024. Non-GAAP1 net loss for the third quarter 2025 of $7.3 million compared to a non-GAAP(1) net loss of $4.8 million for the same period in 2024. \n</p>\n<p>\n     Conference Call Details \n</p>\n<pre style=\"white-space: pre\">\n   -- Iterum will host a conference call today, Friday, November 14, 2025 at \n      8:30 a.m. Eastern Time. The dial-in information for the call is as \n      follows: United States: 1 833 470 1428; International: 1 404 975 4839; \n      Access code: 459214 \n</pre>\n<p>\n     Non-GAAP Financial Measures \n</p>\n<p>\n     To supplement Iterum's financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), Iterum presents non-GAAP net loss and non-GAAP net loss per share to exclude from reported GAAP net loss and GAAP net loss per share, intangible asset amortization ($0.3 million and $1.0 million); share-based compensation expense ($0.1 million and $0.2 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.0 million and $0.1 million); the non-cash amortization of the Exchangeable Notes ($0.0 million and $0.2 million); the interest expense associated with accrued interest on the promissory note issued to Pfizer ($0.6 million and $1.4 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.7 million and $1.8 million) for the three and nine months ended September 30, 2025, and share-based compensation expense ($0.1 million and $0.3 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.2 million and $0.6 million); the non-cash amortization of the Exchangeable Notes ($0.6 million and $1.7 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.4 million and $1.2 million) for the three and nine months ended September 30, 2024. \n</p>\n<p>\n     Iterum believes that the presentation of non-GAAP net loss and non-GAAP net loss per share, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by investors, analysts, and Iterum's management in assessing Iterum's performance and results from period to period. These non-GAAP financial measures closely align with the way management measures and evaluates Iterum's performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net loss or other financial measures calculated in accordance with GAAP. Non-GAAP net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and represents GAAP net loss, which is the most directly comparable GAAP measure, adjusted to exclude intangible asset amortization; share-based compensation expense; the interest expense associated with accrued interest on the Exchangeable Notes; the non-cash amortization of the Exchangeable Notes; the interest expense associated with accrued interest on the promissory note issued to Pfizer; and the non-cash adjustments to the fair value of the Royalty-Linked Notes for the three and nine months ended September 30, 2025 and September 30, 2024. Because of the non-standardized definitions of non-GAAP financial measures, non-GAAP net loss and non-GAAP net loss per share used by Iterum in this press release and accompanying tables has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconciliation of non-GAAP net loss to GAAP net loss and non-GAAP net loss per share to GAAP net loss per share have been provided in the tables included in this press release. \n</p>\n<p>\n     About Iterum Therapeutics plc \n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its New Drug Application (NDA) for ORLYNVAH(TM) (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com. \n</p>\n<p>\n     About ORLYNVAH(TM) \n</p>\n<p>\n     ORLYNVAH(TM) is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH(TM) possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. \n</p>\n<p>\n     Cautionary Note Regarding Forward-looking Statements \n</p>\n<p>\n     This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including our expectation that ORLYNVAH(TM) 2026 net product sales will be between $5 million and $15 million, the development, therapeutic and market potential of ORLYNVAH(TM) and the sufficiency of Iterum's cash resources to fund its operating expenses into the second quarter of 2026. In some cases, forward-looking statements can be identified by words such as \"may,\" \"believes,\" \"intends,\" \"seeks,\" \"anticipates,\" \"plans,\" \"estimates,\" \"expects,\" \"should,\" \"assumes,\" \"continues,\" \"could,\" \"would,\" \"will,\" \"future,\" \"potential\" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including risks and uncertainties concerning Iterum's ability to raise sufficient capital and successfully implement its commercialization plans for ORLYNVAH(TM) with its commercial partner, EVERSANA, including Iterum's ability to expand and maintain a sales force, the protection provided by Iterum's patents, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing its commercialization of ORLYNVAH(TM), the market opportunity for and the potential market acceptance of ORLYNVAH(TM) for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, uptake of ORLYNVAH(TM) by physicians and payer coverage, existing or new competition for ORLYNVAH(TM), Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption \"Risk Factors\" in its Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. \n</p>\n<p>\n     Investor Contact: \n</p>\n<p>\n     Judy Matthews \n</p>\n<p>\n     Chief Financial Officer 312-778-6073 \n</p>\n<p>\n     IR@iterumtx.com \n</p>\n<p>\n     (1) Definition and reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release \n</p>\n<pre style=\"white-space: pre\">\n \n                        ITERUM THERAPEUTICS PLC \n             Condensed Consolidated Statement of Operations \n             (In thousands except share and per share data) \n                              (Unaudited) \n \n                      Three Months Ended          Nine Months Ended \n                        September 30,               September 30, \n                      2025          2024          2025          2024 \nProduct Revenue, \n net              $       390   $        --   $       390   $        -- \n \nCosts and \nexpenses: \nCost of sales     $       (20)  $        --   $       (20)  $        -- \nAmortization of \n intangible \n asset                   (349)           --        (1,036)           -- \nResearch and \n development           (1,261)       (3,107)       (2,852)       (9,159) \nSelling, general \n and \n administrative        (6,491)       (1,780)      (13,452)       (5,867) \nTotal operating \n expenses              (8,121)       (4,887)      (17,360)      (15,026) \n                   ----------    ----------    ----------    ---------- \nOperating loss         (7,731)       (4,887)      (16,970)      (15,026) \nInterest \n expense, net            (441)         (590)       (1,291)       (1,648) \nAdjustments to \n fair value of \n derivatives             (673)         (433)       (1,807)       (1,226) \nOther expense, \n net                       (2)          (48)          (60)          (77) \nIncome tax \n expense                 (132)         (136)         (251)         (215) \nNet loss          $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share -- basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nWeighted average \n ordinary shares \n outstanding -- \n basic and \n diluted           45,801,927    20,044,270    39,975,269    17,352,918 \n                   ==========    ==========    ==========    ========== \n \nReconciliation \nof non-GAAP net \nloss to GAAP \nnet loss \n--------------- \nNet loss - GAAP   $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \nIntangible asset \n amortization             349            --         1,036            -- \nShare based \n compensation              53            68           170           274 \nInterest expense \n - accrued \n interest and \n amortization on \n Exchangeable \n Notes                     --           756           282         2,255 \nInterest on \n promissory note \n - non-cash               562            --         1,415            -- \nAdjustments to \n fair value of \n derivatives              673           433         1,807         1,226 \nNon-GAAP net \n loss             $    (7,342)  $    (4,837)  $   (15,669)  $   (14,437) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share - basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nNon-GAAP net \n loss per share \n - basic and \n diluted          $     (0.16)  $     (0.24)  $     (0.39)  $     (0.83) \n                   ==========    ==========    ==========    ========== \n \n \n \n                     ITERUM THERAPEUTICS PLC \n            Condensed Consolidated Balance Sheet Data \n                          (In thousands) \n                           (Unaudited) \n \n                                        As of           As of \n                                    September 30,    December 31, \n                                          2025            2024 \nCash, cash equivalents and \n short-term investments             $      11,002    $     24,125 \nAccounts receivable                           448              -- \nInventory                                   1,149              -- \nIntangible asset, net                      18,710          19,746 \nOther assets                                1,194             724 \nTotal assets                        $      32,503    $     44,595 \nPfizer Promissory Note              $      21,215    $     20,300 \nExchangeable notes                             --          14,463 \nRoyalty-linked notes                       12,520          10,771 \nOther liabilities                           6,149           3,142 \nTotal liabilities                          39,884          48,676 \nTotal shareholders' deficit                (7,381)         (4,081) \nTotal liabilities and \n shareholders' deficit              $      32,503    $     44,595 \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2025 07:00 ET (12:00 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","03160":"华夏日股对冲","BK4539":"次新股","BK4604":"机器人概念","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","ITRM":"Iterum Therapeutics Plc","BK4581":"高盛持仓","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4534":"瑞士信贷持仓","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4555":"新能源车","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","CMC":"美国工商五金公司","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4006":"钢铁","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0149725797.USD":"汇丰美国股市经济规模基金","BK4592":"伊斯兰概念","LENZ":"Therapeutics","TM":"丰田汽车","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2583038815","content_text":"--Commercially Launched ORLYNVAH$(TM)$ in the United States in August 2025-- \n\n\n     --Extended Cash Runway into Q2 2026-- \n\n\n     --Company to host conference call today at 8:30amET-- \n\n\n     DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. \n\n\n     \"We are thrilled to have launched ORLYNVAH(TM) in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),\" said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. \"The significance of this milestone cannot be overstated--particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we anticipate modest sales in 2025. Looking ahead to 2026, as we continue to build momentum, we currently expect net product sales of ORLYNVAH(TM) to range between $5 million and $15 million, depending on uptake and payer coverage. We will continue to refine our guidance as market dynamics evolve over the next few quarters.\" \n\n\n     Highlights and Recent Events \n\n\n   -- Launch of ORLYNVAH(TM) for uUTIs in August 2025: Iterum commercially \n      launched ORLYNVAH(TM) in the United States. with its commercialization \n      partner, EVERSANA Life Science Services, LLC (EVERSANA), in August 2025. \n \n   -- Expansion of Patent Estate: Iterum has been granted a patent in China as \n      patent number ZL202180020106.6, entitled \"Combinations of Beta-Lactam \n      Compounds, Probenecid, and Valproic Acid and Uses Thereof\", that covers a \n      combination of sulopenem etzadroxil, probenecid, and valproic acid for \n      treating specified diseases. This Chinese patent is projected to expire \n      in March 2041, absent any patent term extensions, and assuming timely \n      payments of all maintenance fees during the lifetime of the patent. In \n      addition, Iterum has been granted a patent in Mexico as patent number \n      426995, entitled \"Combinations of Beta-Lactam Compounds and Probenecid \n      and Uses Thereof\", that covers a bilayer tablet comprising sulopenem \n      etzadroxil and probenecid, methods of preparing the bilayer tablet, and \n      the bilayer tablet for use in treating specified diseases. This Mexican \n      patent is projected to expire in December 2039, absent any patent term \n      extensions, and assuming timely payments of all maintenance fees during \n      the lifetime of the patent. \n \n   -- Presented at IDWeek: Iterum presented two posters at the Infectious \n      Disease Society of America's IDWeek 2025 conference in October 2025 and \n      conducted a Learning Lounge at IDWeek titled 'An Overview of Urinary \n      Tract Infection in Adult Women: Focus on Oral Sulopenem.' \n\n\n     Third Quarter 2025 Financial Results \n\n\n     Cash and cash equivalents were $11.0 million as of September 30, 2025. Based on Iterum's current operating plan, Iterum expects that its cash and cash equivalents as of September 30, 2025, together with $2.6 million of net proceeds raised under its at-the-market offering program from October 1, 2025 through November 13, 2025, will be sufficient to fund its operations into the second quarter of 2026. As of November 13, 2025, Iterum had approximately 52.8 million ordinary shares outstanding. \n\n\n     Net product revenues for the third quarter 2025 were $0.4 million related to sales of ORLYNVAH(TM) which launched in August 2025 and included initial stocking at Iterum's specialty pharmacy locations for distribution in its targeted territories. \n\n\n     Cost of sales expense for the third quarter 2025 was $0.02 million and primarily consists of royalty payments pursuant to Iterum's license agreement with Pfizer Inc (Pfizer). Prior to approval in October 2024, costs incurred for the manufacture of ORLYNVAH(TM) were recorded as research and development expenses. \n\n\n     Amortization of intangible asset for the third quarter 2025 was $0.3 million and related to the finite-lived intangible asset recognized in relation to the regulatory milestone payment payable to Pfizer upon approval of ORLYNVAH(TM) by the FDA. \n\n\n     Research and development expenses for the third quarter 2025 were $1.3 million compared to $3.1 million for the same period in 2024. The decrease for the three-month period was primarily due to lower chemistry, manufacturing and control $(CMC)$ related expenses. Following approval, costs incurred for the manufacture of ORLYNVAH(TM) have been capitalized to inventory. \n\n\n     Selling, general and administrative expenses for the third quarter 2025 were $6.5 million compared to $1.8 million for the same period in 2024. The increase for the three-month period was primarily due to the commercialization of ORLYNVAH(TM), which was launched in August 2025. \n\n\n     Adjustments to the fair value of derivatives for the third quarter 2025 was $0.7 million compared to $0.4 million for the same period in 2024. The non-cash adjustment for the third quarter 2025 and 2024 primarily related to an increase in the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the Royalty-Linked Notes) due to the passage of time. \n\n\n     Net loss for the third quarter 2025 was $9.0 million compared to a net loss of $6.1 million for the same period in 2024. Non-GAAP1 net loss for the third quarter 2025 of $7.3 million compared to a non-GAAP(1) net loss of $4.8 million for the same period in 2024. \n\n\n     Conference Call Details \n\n\n   -- Iterum will host a conference call today, Friday, November 14, 2025 at \n      8:30 a.m. Eastern Time. The dial-in information for the call is as \n      follows: United States: 1 833 470 1428; International: 1 404 975 4839; \n      Access code: 459214 \n\n\n     Non-GAAP Financial Measures \n\n\n     To supplement Iterum's financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), Iterum presents non-GAAP net loss and non-GAAP net loss per share to exclude from reported GAAP net loss and GAAP net loss per share, intangible asset amortization ($0.3 million and $1.0 million); share-based compensation expense ($0.1 million and $0.2 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.0 million and $0.1 million); the non-cash amortization of the Exchangeable Notes ($0.0 million and $0.2 million); the interest expense associated with accrued interest on the promissory note issued to Pfizer ($0.6 million and $1.4 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.7 million and $1.8 million) for the three and nine months ended September 30, 2025, and share-based compensation expense ($0.1 million and $0.3 million); the interest expense associated with accrued interest on the Exchangeable Notes ($0.2 million and $0.6 million); the non-cash amortization of the Exchangeable Notes ($0.6 million and $1.7 million); and the non-cash adjustments to the fair value of the Royalty-Linked Notes ($0.4 million and $1.2 million) for the three and nine months ended September 30, 2024. \n\n\n     Iterum believes that the presentation of non-GAAP net loss and non-GAAP net loss per share, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by investors, analysts, and Iterum's management in assessing Iterum's performance and results from period to period. These non-GAAP financial measures closely align with the way management measures and evaluates Iterum's performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net loss or other financial measures calculated in accordance with GAAP. Non-GAAP net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and represents GAAP net loss, which is the most directly comparable GAAP measure, adjusted to exclude intangible asset amortization; share-based compensation expense; the interest expense associated with accrued interest on the Exchangeable Notes; the non-cash amortization of the Exchangeable Notes; the interest expense associated with accrued interest on the promissory note issued to Pfizer; and the non-cash adjustments to the fair value of the Royalty-Linked Notes for the three and nine months ended September 30, 2025 and September 30, 2024. Because of the non-standardized definitions of non-GAAP financial measures, non-GAAP net loss and non-GAAP net loss per share used by Iterum in this press release and accompanying tables has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconciliation of non-GAAP net loss to GAAP net loss and non-GAAP net loss per share to GAAP net loss per share have been provided in the tables included in this press release. \n\n\n     About Iterum Therapeutics plc \n\n\n\n     Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its New Drug Application (NDA) for ORLYNVAH(TM) (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com. \n\n\n     About ORLYNVAH(TM) \n\n\n     ORLYNVAH(TM) is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH(TM) possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. \n\n\n     Cautionary Note Regarding Forward-looking Statements \n\n\n     This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including our expectation that ORLYNVAH(TM) 2026 net product sales will be between $5 million and $15 million, the development, therapeutic and market potential of ORLYNVAH(TM) and the sufficiency of Iterum's cash resources to fund its operating expenses into the second quarter of 2026. In some cases, forward-looking statements can be identified by words such as \"may,\" \"believes,\" \"intends,\" \"seeks,\" \"anticipates,\" \"plans,\" \"estimates,\" \"expects,\" \"should,\" \"assumes,\" \"continues,\" \"could,\" \"would,\" \"will,\" \"future,\" \"potential\" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including risks and uncertainties concerning Iterum's ability to raise sufficient capital and successfully implement its commercialization plans for ORLYNVAH(TM) with its commercial partner, EVERSANA, including Iterum's ability to expand and maintain a sales force, the protection provided by Iterum's patents, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing its commercialization of ORLYNVAH(TM), the market opportunity for and the potential market acceptance of ORLYNVAH(TM) for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, uptake of ORLYNVAH(TM) by physicians and payer coverage, existing or new competition for ORLYNVAH(TM), Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption \"Risk Factors\" in its Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. \n\n\n     Investor Contact: \n\n\n     Judy Matthews \n\n\n     Chief Financial Officer 312-778-6073 \n\n\n     IR@iterumtx.com \n\n\n     (1) Definition and reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release \n\n\n \n                        ITERUM THERAPEUTICS PLC \n             Condensed Consolidated Statement of Operations \n             (In thousands except share and per share data) \n                              (Unaudited) \n \n                      Three Months Ended          Nine Months Ended \n                        September 30,               September 30, \n                      2025          2024          2025          2024 \nProduct Revenue, \n net              $       390   $        --   $       390   $        -- \n \nCosts and \nexpenses: \nCost of sales     $       (20)  $        --   $       (20)  $        -- \nAmortization of \n intangible \n asset                   (349)           --        (1,036)           -- \nResearch and \n development           (1,261)       (3,107)       (2,852)       (9,159) \nSelling, general \n and \n administrative        (6,491)       (1,780)      (13,452)       (5,867) \nTotal operating \n expenses              (8,121)       (4,887)      (17,360)      (15,026) \n                   ----------    ----------    ----------    ---------- \nOperating loss         (7,731)       (4,887)      (16,970)      (15,026) \nInterest \n expense, net            (441)         (590)       (1,291)       (1,648) \nAdjustments to \n fair value of \n derivatives             (673)         (433)       (1,807)       (1,226) \nOther expense, \n net                       (2)          (48)          (60)          (77) \nIncome tax \n expense                 (132)         (136)         (251)         (215) \nNet loss          $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share -- basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nWeighted average \n ordinary shares \n outstanding -- \n basic and \n diluted           45,801,927    20,044,270    39,975,269    17,352,918 \n                   ==========    ==========    ==========    ========== \n \nReconciliation \nof non-GAAP net \nloss to GAAP \nnet loss \n--------------- \nNet loss - GAAP   $    (8,979)  $    (6,094)  $   (20,379)  $   (18,192) \nIntangible asset \n amortization             349            --         1,036            -- \nShare based \n compensation              53            68           170           274 \nInterest expense \n - accrued \n interest and \n amortization on \n Exchangeable \n Notes                     --           756           282         2,255 \nInterest on \n promissory note \n - non-cash               562            --         1,415            -- \nAdjustments to \n fair value of \n derivatives              673           433         1,807         1,226 \nNon-GAAP net \n loss             $    (7,342)  $    (4,837)  $   (15,669)  $   (14,437) \n                   ==========    ==========    ==========    ========== \nNet loss per \n share - basic \n and diluted      $     (0.20)  $     (0.30)  $     (0.51)  $     (1.05) \n                   ==========    ==========    ==========    ========== \nNon-GAAP net \n loss per share \n - basic and \n diluted          $     (0.16)  $     (0.24)  $     (0.39)  $     (0.83) \n                   ==========    ==========    ==========    ========== \n \n \n \n                     ITERUM THERAPEUTICS PLC \n            Condensed Consolidated Balance Sheet Data \n                          (In thousands) \n                           (Unaudited) \n \n                                        As of           As of \n                                    September 30,    December 31, \n                                          2025            2024 \nCash, cash equivalents and \n short-term investments             $      11,002    $     24,125 \nAccounts receivable                           448              -- \nInventory                                   1,149              -- \nIntangible asset, net                      18,710          19,746 \nOther assets                                1,194             724 \nTotal assets                        $      32,503    $     44,595 \nPfizer Promissory Note              $      21,215    $     20,300 \nExchangeable notes                             --          14,463 \nRoyalty-linked notes                       12,520          10,771 \nOther liabilities                           6,149           3,142 \nTotal liabilities                          39,884          48,676 \nTotal shareholders' deficit                (7,381)         (4,081) \nTotal liabilities and \n shareholders' deficit              $      32,503    $     44,595 \n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 07:00 ET (12:00 GMT)","news_type":1,"symbols_score_info":{"CMC":1,"LENZ":1.5,"ITRM":0.9,"TM":1,"03160":0.6}},"isVote":1,"tweetType":1,"viewCount":518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":501513085473232,"gmtCreate":1763449361341,"gmtModify":1763449364605,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"🚀❤️","listText":"🚀❤️","text":"🚀❤️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/501513085473232","repostId":"2583503898","repostType":2,"repost":{"id":"2583503898","kind":"live","pubTimestamp":1763121934,"share":"https://ttm.financial/m/news/2583503898?lang=en_US&edition=fundamental","pubTime":"2025-11-14 20:05","market":"nz","language":"en","title":"Iterum Therapeutics Q3 Adjusted EPS USD -0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503898","media":"THOMSON REUTERS","summary":"Iterum Therapeutics Q3 Adjusted EPS USD -0.16","content":"<html><body><p>Iterum Therapeutics Q3 Adjusted EPS USD -0.16</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iterum Therapeutics Q3 Adjusted EPS USD -0.16</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIterum Therapeutics Q3 Adjusted EPS USD -0.16\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-14 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX7B8088:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iterum Therapeutics Q3 Adjusted EPS USD -0.16</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX7B8088:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","ITRM":"Iterum Therapeutics Plc"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX7B8088:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2583503898","content_text":"Iterum Therapeutics Q3 Adjusted EPS USD -0.16","news_type":1,"symbols_score_info":{"ITRM":0.9}},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":501487531024608,"gmtCreate":1763443012346,"gmtModify":1763443016499,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"LAES buy and hold&nbsp; wait till&nbsp; Nov 21 👏🏻🥳🚀","listText":"LAES buy and hold&nbsp; wait till&nbsp; Nov 21 👏🏻🥳🚀","text":"LAES buy and hold wait till Nov 21 👏🏻🥳🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/501487531024608","repostId":"2584674518","repostType":2,"repost":{"id":"2584674518","kind":"highlight","pubTimestamp":1763413810,"share":"https://ttm.financial/m/news/2584674518?lang=en_US&edition=fundamental","pubTime":"2025-11-18 05:10","market":"fut","language":"en","title":"Mixed options sentiment in Sealsq Corp with shares down 8.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584674518","media":"TIPRANKS","summary":"Mixed options sentiment in Sealsq Corp (LAES), with shares down 36c near $4.12. Options volume relatively light with 42k contracts traded and calls...","content":"<div>\n<p>Mixed options sentiment in Sealsq Corp (LAES), with shares down 36c near $4.12. Options volume relatively light with 42k contracts traded and calls...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sealsq-corp-with-shares-down-8-13-thefly?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mixed options sentiment in Sealsq Corp with shares down 8.13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMixed options sentiment in Sealsq Corp with shares down 8.13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-18 05:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sealsq-corp-with-shares-down-8-13-thefly?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mixed options sentiment in Sealsq Corp (LAES), with shares down 36c near $4.12. Options volume relatively light with 42k contracts traded and calls...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sealsq-corp-with-shares-down-8-13-thefly?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LAES":"SEALSQ Corp","BK4141":"半导体产品"},"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sealsq-corp-with-shares-down-8-13-thefly?utm_source=itigerup.com&utm_medium=referral","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2584674518","content_text":"Mixed options sentiment in Sealsq Corp (LAES), with shares down 36c near $4.12. Options volume relatively light with 42k contracts traded and calls...","news_type":1,"symbols_score_info":{"LAES":1}},"isVote":1,"tweetType":1,"viewCount":632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":499951531504160,"gmtCreate":1763083554440,"gmtModify":1763083556690,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/LAES\">$SEALSQ Corp(LAES)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/LAES\">$SEALSQ Corp(LAES)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$SEALSQ Corp(LAES)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/499951531504160","isVote":1,"tweetType":1,"viewCount":549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":497349725414072,"gmtCreate":1762445785802,"gmtModify":1762445789062,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"up","listText":"up","text":"up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/497349725414072","repostId":"2580782480","repostType":2,"repost":{"id":"2580782480","kind":"highlight","pubTimestamp":1762252522,"share":"https://ttm.financial/m/news/2580782480?lang=en_US&edition=fundamental","pubTime":"2025-11-04 18:35","market":"fut","language":"en","title":"WISeKey, Sealsq provide update on Swiss Armed Forces collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2580782480","media":"TIPRANKS","summary":"WISeKey (WKEY) and Sealsq (LAES) provided an update on the evolution of its collaboration with the Swiss Armed Forces. This partnership, initiated ...","content":"<div>\n<p>WISeKey (WKEY) and Sealsq (LAES) provided an update on the evolution of its collaboration with the Swiss Armed Forces. This partnership, initiated ...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/wisekey-sealsq-provide-update-on-swiss-armed-forces-collaboration-thefly?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WISeKey, Sealsq provide update on Swiss Armed Forces collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWISeKey, Sealsq provide update on Swiss Armed Forces collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-04 18:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/the-fly/wisekey-sealsq-provide-update-on-swiss-armed-forces-collaboration-thefly?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WISeKey (WKEY) and Sealsq (LAES) provided an update on the evolution of its collaboration with the Swiss Armed Forces. This partnership, initiated ...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/wisekey-sealsq-provide-update-on-swiss-armed-forces-collaboration-thefly?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WKEY":"Wisekey International Holding AG","BK4141":"半导体产品","LAES":"SEALSQ Corp","BK4565":"NFT概念"},"source_url":"https://www.tipranks.com/news/the-fly/wisekey-sealsq-provide-update-on-swiss-armed-forces-collaboration-thefly?utm_source=itigerup.com&utm_medium=referral","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2580782480","content_text":"WISeKey (WKEY) and Sealsq (LAES) provided an update on the evolution of its collaboration with the Swiss Armed Forces. This partnership, initiated ...","news_type":1,"symbols_score_info":{"LAES":1,"WKEY":1}},"isVote":1,"tweetType":1,"viewCount":1006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":496862692463496,"gmtCreate":1762326823275,"gmtModify":1762326827328,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"BUY&nbsp;","listText":"BUY&nbsp;","text":"BUY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496862692463496","repostId":"2572510315","repostType":2,"repost":{"id":"2572510315","kind":"highlight","pubTimestamp":1759410926,"share":"https://ttm.financial/m/news/2572510315?lang=en_US&edition=fundamental","pubTime":"2025-10-02 21:15","market":"nz","language":"en","title":"Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572510315","media":"TIPRANKS","summary":"Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares close...","content":"<div>\n<p>Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares close...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-02 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares close...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ITRM":"Iterum Therapeutics Plc"},"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2572510315","content_text":"Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares close...","news_type":1,"symbols_score_info":{"ITRM":1.5}},"isVote":1,"tweetType":1,"viewCount":1124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":495176985101112,"gmtCreate":1761923405178,"gmtModify":1761923408273,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"👌🏻🥳","listText":"👌🏻🥳","text":"👌🏻🥳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/495176985101112","repostId":"2579156464","repostType":2,"repost":{"id":"2579156464","kind":"highlight","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1761914700,"share":"https://ttm.financial/m/news/2579156464?lang=en_US&edition=fundamental","pubTime":"2025-10-31 20:45","market":"hk","language":"en","title":"SEALSQ and IC’Alps Unify Expertise to Deliver Integrated Post-Quantum Cybersecurity and Functional Safety for Autonomous Vehicles","url":"https://stock-news.laohu8.com/highlight/detail?id=2579156464","media":"GlobeNewswire","summary":"Geneva, Switzerland, Oct.  31, 2025  (GLOBE NEWSWIRE) --   SEALSQ Corp (NASDAQ: LAES) (\"SEALSQ\" or \"Company\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum te","content":"<html><body>Geneva, Switzerland, Oct.  31, 2025  (GLOBE NEWSWIRE) --   <p><a href=\"https://laohu8.com/S/LAES\">SEALSQ Corp</a> (NASDAQ: LAES) (\"SEALSQ\" or \"Company\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-<a href=\"https://laohu8.com/S/QMCO\">Quantum</a> technology hardware and software products, today announced a new initiative leveraging the expertise of its subsidiary IC’Alps to develop integrated cybersecurity and functional safety solutions for the global automotive industry.</p> <p><img height=\"362.67px\" src=\"https://ml.globenewswire.com/Resource/Download/4dfb7d0e-88b7-4969-862f-35a2d2d0d1ca/image2.jpeg\" width=\"362.67px\"/>This initiative aims to position SEALSQ at the forefront of protecting next-generation autonomous and connected vehicles against emerging cybersecurity threats. Autonomous and software-defined vehicles are becoming highly interconnected digital platforms, relying on over-the-air (OTA) updates, vehicle-to-everything (V2X) communication, and advanced sensor fusion capabilities. However, classical cryptographic systems, such as RSA and ECDSA, are vulnerable to future quantum computer attacks, which could compromise vehicle control systems, data integrity, navigation, and safety.</p> <p>With autonomous vehicles becoming mission-critical systems, cybersecurity and functional safety must evolve together. SEALSQ plans to leverage its secure semiconductor technology in combination with the expertise of its subsidiary IC’Alps, a leader in custom ASIC design for safety-critical industries.</p> <p>Because it is cheaper and always safer to prevent, rather than correct failure consequences, IC’Alps applies Failure Modes and Effects Analysis (FMEA) as a core methodology to detect, mitigate, and prevent potential systematic failures as early as possible. As ASICs frequently power critical system functions in automotive, IC’Alps integrates DFMEA (Design FMEA) into its design strategy in full compliance with IATF 16949 and other safety-sensitive industry standards such as medical devices (ISO 13485) and aeronautics (AS 9100 / JISQ 9100 / EN 9100). This proactive approach aims to ensure reliability, quality, and long-term operational integrity.</p> <p>Additionally, these processes can directly support customers targeting ISO 26262 certification and developing systems across ASIL-A to ASIL-D levels. FMEA is a cornerstone of the technical risk management process under IATF 16949, ensuring robustness in design and production by anticipating and preventing failures that could affect yield, reliability, and safety. IC’Alps has developed and continued to develop critical IP blocks and complete ASICs for demanding automotive applications for worldwide leading semiconductor players, and Tier 1 suppliers, up to ASIL certification.</p> <p>With IC’Alps’ expertise in DFMEA, ASIC development rigor, and activities dealing with ISO 21434 (automotive cybersecurity), SEALSQ ensures its secure silicon meets the highest standards of both cybersecurity resilience and functional safety for the automotive industry.<br/>https://www.icalps.com/fr/how-fmea-tools-translates-to-automotive-asic-design-at-icalps/</p> <p><strong>Why Post-Quantum Security is Critical for Autonomous Vehicles</strong></p> <p>As vehicles evolve into fully connected, software-defined systems, cybersecurity is no longer optional, it is foundational to safety, reliability, and consumer trust. Post-quantum security represents the next frontier in protecting these intelligent platforms from emerging threats including:</p> <ul type=\"disc\"><li><u>Imminent quantum vulnerability:</u> Classical encryption protecting vehicles today will be breakable by quantum computers.</li><li><u>Growing connectivity risks</u>: Constant OTA and V2X interactions expand attack surfaces.</li><li><u>Future-proofing safety and trust:</u> Post-quantum cryptography (PQC) implementation ensures long-term vehicle integrity and secure autonomy.<br/><br/></li></ul> <p>\"The future of mobility must be secure by design, not only for today, but for the quantum era,\" said Carlos Moreira, Founder &amp; CEO of SEALSQ. \"By combining SEALSQ’s post-quantum cybersecurity leadership with IC’Alps' world-class ASIC safety methodology, we aim to ensure autonomous vehicles remain protected, reliable, and trusted for decades ahead.\"</p> <p><strong>About SEALSQ:</strong></p> <p>SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.</p> <p>SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.</p> <p>For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.</p> <p><strong>Forward-Looking Statements</strong><br/>This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.</p> <p>SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.</p> <table><tr><td>SEALSQ Corp.<br/>Carlos Moreira<br/>Chairman &amp; CEO<br/>Tel: +41 22 594 3000<br/>info@sealsq.com</td><td>SEALSQ Investor Relations (US)<br/>The Equity Group Inc.<br/>Lena Cati<br/>Tel: +1 212 836-9611 <br/>lcati@theequitygruop.com<br/><br/></td></tr></table> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZGI1MzViNTktNWE3ZS00NmNiLThjMzAtNzUzY2I0N2MzYTA4LTEyNjY0MDUtMjAyNS0xMC0zMS1lbg==/tiny/SEAL-Semiconductors.png\"/></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEALSQ and IC’Alps Unify Expertise to Deliver Integrated Post-Quantum Cybersecurity and Functional Safety for Autonomous Vehicles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEALSQ and IC’Alps Unify Expertise to Deliver Integrated Post-Quantum Cybersecurity and Functional Safety for Autonomous Vehicles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-10-31 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Geneva, Switzerland, Oct.  31, 2025  (GLOBE NEWSWIRE) --   <p><a href=\"https://laohu8.com/S/LAES\">SEALSQ Corp</a> (NASDAQ: LAES) (\"SEALSQ\" or \"Company\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-<a href=\"https://laohu8.com/S/QMCO\">Quantum</a> technology hardware and software products, today announced a new initiative leveraging the expertise of its subsidiary IC’Alps to develop integrated cybersecurity and functional safety solutions for the global automotive industry.</p> <p><img height=\"362.67px\" src=\"https://ml.globenewswire.com/Resource/Download/4dfb7d0e-88b7-4969-862f-35a2d2d0d1ca/image2.jpeg\" width=\"362.67px\"/>This initiative aims to position SEALSQ at the forefront of protecting next-generation autonomous and connected vehicles against emerging cybersecurity threats. Autonomous and software-defined vehicles are becoming highly interconnected digital platforms, relying on over-the-air (OTA) updates, vehicle-to-everything (V2X) communication, and advanced sensor fusion capabilities. However, classical cryptographic systems, such as RSA and ECDSA, are vulnerable to future quantum computer attacks, which could compromise vehicle control systems, data integrity, navigation, and safety.</p> <p>With autonomous vehicles becoming mission-critical systems, cybersecurity and functional safety must evolve together. SEALSQ plans to leverage its secure semiconductor technology in combination with the expertise of its subsidiary IC’Alps, a leader in custom ASIC design for safety-critical industries.</p> <p>Because it is cheaper and always safer to prevent, rather than correct failure consequences, IC’Alps applies Failure Modes and Effects Analysis (FMEA) as a core methodology to detect, mitigate, and prevent potential systematic failures as early as possible. As ASICs frequently power critical system functions in automotive, IC’Alps integrates DFMEA (Design FMEA) into its design strategy in full compliance with IATF 16949 and other safety-sensitive industry standards such as medical devices (ISO 13485) and aeronautics (AS 9100 / JISQ 9100 / EN 9100). This proactive approach aims to ensure reliability, quality, and long-term operational integrity.</p> <p>Additionally, these processes can directly support customers targeting ISO 26262 certification and developing systems across ASIL-A to ASIL-D levels. FMEA is a cornerstone of the technical risk management process under IATF 16949, ensuring robustness in design and production by anticipating and preventing failures that could affect yield, reliability, and safety. IC’Alps has developed and continued to develop critical IP blocks and complete ASICs for demanding automotive applications for worldwide leading semiconductor players, and Tier 1 suppliers, up to ASIL certification.</p> <p>With IC’Alps’ expertise in DFMEA, ASIC development rigor, and activities dealing with ISO 21434 (automotive cybersecurity), SEALSQ ensures its secure silicon meets the highest standards of both cybersecurity resilience and functional safety for the automotive industry.<br/>https://www.icalps.com/fr/how-fmea-tools-translates-to-automotive-asic-design-at-icalps/</p> <p><strong>Why Post-Quantum Security is Critical for Autonomous Vehicles</strong></p> <p>As vehicles evolve into fully connected, software-defined systems, cybersecurity is no longer optional, it is foundational to safety, reliability, and consumer trust. Post-quantum security represents the next frontier in protecting these intelligent platforms from emerging threats including:</p> <ul type=\"disc\"><li><u>Imminent quantum vulnerability:</u> Classical encryption protecting vehicles today will be breakable by quantum computers.</li><li><u>Growing connectivity risks</u>: Constant OTA and V2X interactions expand attack surfaces.</li><li><u>Future-proofing safety and trust:</u> Post-quantum cryptography (PQC) implementation ensures long-term vehicle integrity and secure autonomy.<br/><br/></li></ul> <p>\"The future of mobility must be secure by design, not only for today, but for the quantum era,\" said Carlos Moreira, Founder &amp; CEO of SEALSQ. \"By combining SEALSQ’s post-quantum cybersecurity leadership with IC’Alps' world-class ASIC safety methodology, we aim to ensure autonomous vehicles remain protected, reliable, and trusted for decades ahead.\"</p> <p><strong>About SEALSQ:</strong></p> <p>SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.</p> <p>SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.</p> <p>For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.</p> <p><strong>Forward-Looking Statements</strong><br/>This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.</p> <p>SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.</p> <table><tr><td>SEALSQ Corp.<br/>Carlos Moreira<br/>Chairman &amp; CEO<br/>Tel: +41 22 594 3000<br/>info@sealsq.com</td><td>SEALSQ Investor Relations (US)<br/>The Equity Group Inc.<br/>Lena Cati<br/>Tel: +1 212 836-9611 <br/>lcati@theequitygruop.com<br/><br/></td></tr></table> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZGI1MzViNTktNWE3ZS00NmNiLThjMzAtNzUzY2I0N2MzYTA4LTEyNjY0MDUtMjAyNS0xMC0zMS1lbg==/tiny/SEAL-Semiconductors.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTSK":"Netskope, Inc.","ECC":"Eagle Point Credit Co LLC","BK4097":"系统软件","BK4141":"半导体产品","LAES":"SEALSQ Corp","BK4212":"包装食品与肉类","POST":"Post Holdings"},"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178329/0/en/SEALSQ-and-IC-Alps-Unify-Expertise-to-Deliver-Integrated-Post-Quantum-Cybersecurity-and-Functional-Safety-for-Autonomous-Vehicles.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2579156464","content_text":"Geneva, Switzerland, Oct.  31, 2025  (GLOBE NEWSWIRE) --   SEALSQ Corp (NASDAQ: LAES) (\"SEALSQ\" or \"Company\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a new initiative leveraging the expertise of its subsidiary IC’Alps to develop integrated cybersecurity and functional safety solutions for the global automotive industry. This initiative aims to position SEALSQ at the forefront of protecting next-generation autonomous and connected vehicles against emerging cybersecurity threats. Autonomous and software-defined vehicles are becoming highly interconnected digital platforms, relying on over-the-air (OTA) updates, vehicle-to-everything (V2X) communication, and advanced sensor fusion capabilities. However, classical cryptographic systems, such as RSA and ECDSA, are vulnerable to future quantum computer attacks, which could compromise vehicle control systems, data integrity, navigation, and safety. With autonomous vehicles becoming mission-critical systems, cybersecurity and functional safety must evolve together. SEALSQ plans to leverage its secure semiconductor technology in combination with the expertise of its subsidiary IC’Alps, a leader in custom ASIC design for safety-critical industries. Because it is cheaper and always safer to prevent, rather than correct failure consequences, IC’Alps applies Failure Modes and Effects Analysis (FMEA) as a core methodology to detect, mitigate, and prevent potential systematic failures as early as possible. As ASICs frequently power critical system functions in automotive, IC’Alps integrates DFMEA (Design FMEA) into its design strategy in full compliance with IATF 16949 and other safety-sensitive industry standards such as medical devices (ISO 13485) and aeronautics (AS 9100 / JISQ 9100 / EN 9100). This proactive approach aims to ensure reliability, quality, and long-term operational integrity. Additionally, these processes can directly support customers targeting ISO 26262 certification and developing systems across ASIL-A to ASIL-D levels. FMEA is a cornerstone of the technical risk management process under IATF 16949, ensuring robustness in design and production by anticipating and preventing failures that could affect yield, reliability, and safety. IC’Alps has developed and continued to develop critical IP blocks and complete ASICs for demanding automotive applications for worldwide leading semiconductor players, and Tier 1 suppliers, up to ASIL certification. With IC’Alps’ expertise in DFMEA, ASIC development rigor, and activities dealing with ISO 21434 (automotive cybersecurity), SEALSQ ensures its secure silicon meets the highest standards of both cybersecurity resilience and functional safety for the automotive industry.https://www.icalps.com/fr/how-fmea-tools-translates-to-automotive-asic-design-at-icalps/ Why Post-Quantum Security is Critical for Autonomous Vehicles As vehicles evolve into fully connected, software-defined systems, cybersecurity is no longer optional, it is foundational to safety, reliability, and consumer trust. Post-quantum security represents the next frontier in protecting these intelligent platforms from emerging threats including: Imminent quantum vulnerability: Classical encryption protecting vehicles today will be breakable by quantum computers.Growing connectivity risks: Constant OTA and V2X interactions expand attack surfaces.Future-proofing safety and trust: Post-quantum cryptography (PQC) implementation ensures long-term vehicle integrity and secure autonomy. \"The future of mobility must be secure by design, not only for today, but for the quantum era,\" said Carlos Moreira, Founder & CEO of SEALSQ. \"By combining SEALSQ’s post-quantum cybersecurity leadership with IC’Alps' world-class ASIC safety methodology, we aim to ensure autonomous vehicles remain protected, reliable, and trusted for decades ahead.\" About SEALSQ: SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable. SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries. For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com. Forward-Looking StatementsThis communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC. SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SEALSQ Corp.Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@sealsq.comSEALSQ Investor Relations (US)The Equity Group Inc.Lena CatiTel: +1 212 836-9611 lcati@theequitygruop.com","news_type":1,"symbols_score_info":{"LAES":1,"POST":1.5,"NTSK":1.5,"ECC":1}},"isVote":1,"tweetType":1,"viewCount":736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":494893013790840,"gmtCreate":1761854399845,"gmtModify":1761854403667,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494893013790840","repostId":"1120212546","repostType":2,"repost":{"id":"1120212546","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1761739382,"share":"https://ttm.financial/m/news/1120212546?lang=en_US&edition=fundamental","pubTime":"2025-10-29 20:03","market":"sg","language":"en","title":"Stock Track | SEALSQ Corp Soars 5.49% Pre-market on Strategic Partnership for Satellite Launch Services","url":"https://stock-news.laohu8.com/highlight/detail?id=1120212546","media":"Stock Track","summary":"SEALSQ Corp (LAES) saw its stock surge 5.49% in pre-market trading on Wednesday, following the announcement of a strategic partnership in the satellite launch services sector. The company, along with...","content":"<p>SEALSQ Corp (LAES) saw its stock surge 5.49% in pre-market trading on Wednesday, following the announcement of a strategic partnership in the satellite launch services sector. The company, along with its parent WISeKey International (WKEY) and sister subsidiary WISeSat.Space, has signed a memorandum of understanding (MoU) with INNOSPACE, a South Korean satellite launch services provider.</p>\n\n<p>The collaboration aims to advance secure and efficient satellite deployment by diversifying launch sites, potentially opening up new opportunities for SEALSQ in the growing space technology market. While financial terms of the agreement were not disclosed, investors appear optimistic about the potential impact on SEALSQ's future growth prospects.</p>\n\n<p>The pre-market rally in SEALSQ's stock also comes amid a broader uptick in quantum computing shares. Several companies in the sector, including Arqit Quantum, Rigetti Computing, and IonQ, saw their stocks rise in pre-market trading. This sector-wide movement suggests growing investor interest in quantum computing and related technologies, which may have further boosted SEALSQ's stock performance.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SEALSQ Corp Soars 5.49% Pre-market on Strategic Partnership for Satellite Launch Services</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SEALSQ Corp Soars 5.49% Pre-market on Strategic Partnership for Satellite Launch Services\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SEALSQ Corp (LAES) saw its stock surge 5.49% in pre-market trading on Wednesday, following the announcement of a strategic partnership in the satellite launch services sector. The company, along with its parent WISeKey International (WKEY) and sister subsidiary WISeSat.Space, has signed a memorandum of understanding (MoU) with INNOSPACE, a South Korean satellite launch services provider.</p>\n\n<p>The collaboration aims to advance secure and efficient satellite deployment by diversifying launch sites, potentially opening up new opportunities for SEALSQ in the growing space technology market. While financial terms of the agreement were not disclosed, investors appear optimistic about the potential impact on SEALSQ's future growth prospects.</p>\n\n<p>The pre-market rally in SEALSQ's stock also comes amid a broader uptick in quantum computing shares. Several companies in the sector, including Arqit Quantum, Rigetti Computing, and IonQ, saw their stocks rise in pre-market trading. This sector-wide movement suggests growing investor interest in quantum computing and related technologies, which may have further boosted SEALSQ's stock performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LAES":"SEALSQ Corp"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120212546","content_text":"SEALSQ Corp (LAES) saw its stock surge 5.49% in pre-market trading on Wednesday, following the announcement of a strategic partnership in the satellite launch services sector. The company, along with its parent WISeKey International (WKEY) and sister subsidiary WISeSat.Space, has signed a memorandum of understanding (MoU) with INNOSPACE, a South Korean satellite launch services provider.\nThe collaboration aims to advance secure and efficient satellite deployment by diversifying launch sites, potentially opening up new opportunities for SEALSQ in the growing space technology market. While financial terms of the agreement were not disclosed, investors appear optimistic about the potential impact on SEALSQ's future growth prospects.\nThe pre-market rally in SEALSQ's stock also comes amid a broader uptick in quantum computing shares. Several companies in the sector, including Arqit Quantum, Rigetti Computing, and IonQ, saw their stocks rise in pre-market trading. This sector-wide movement suggests growing investor interest in quantum computing and related technologies, which may have further boosted SEALSQ's stock performance.","news_type":1,"symbols_score_info":{"LAES":1}},"isVote":1,"tweetType":1,"viewCount":1050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":455154164687104,"gmtCreate":1752130153512,"gmtModify":1752130156136,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ITRM\">$Iterum Therapeutics Plc(ITRM)$</a> 🎸🚀🙌🏼🎁🎰","listText":"<a href=\"https://ttm.financial/S/ITRM\">$Iterum Therapeutics Plc(ITRM)$</a> 🎸🚀🙌🏼🎁🎰","text":"$Iterum Therapeutics Plc(ITRM)$ 🎸🚀🙌🏼🎁🎰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/455154164687104","isVote":1,"tweetType":1,"viewCount":1792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363116233355272,"gmtCreate":1729694037720,"gmtModify":1729694042850,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> &nbsp;🙏🏻🚀🚀🚀🧨","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> &nbsp;🙏🏻🚀🚀🚀🧨","text":"$Tiger Brokers(TIGR)$ 🙏🏻🚀🚀🚀🧨","images":[{"img":"https://community-static.tradeup.com/news/4ac8e44a616a8a122bf00dc4a7f78e71","width":"1290","height":"1786"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363116233355272","isVote":1,"tweetType":1,"viewCount":1994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360064934047984,"gmtCreate":1728934359763,"gmtModify":1728934362982,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a> 👋🏻🙏🏻","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a> 👋🏻🙏🏻","text":"$NVIDIA Corp(NVDA)$ 👋🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/360064934047984","isVote":1,"tweetType":1,"viewCount":2390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":215231621099640,"gmtCreate":1693577607408,"gmtModify":1693577610014,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SNAP\">$Snap Inc(SNAP)$&nbsp;</a>🍻🍻🍻🎉🙏🏻","listText":"<a href=\"https://ttm.financial/S/SNAP\">$Snap Inc(SNAP)$&nbsp;</a>🍻🍻🍻🎉🙏🏻","text":"$Snap Inc(SNAP)$ 🍻🍻🍻🎉🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/215231621099640","isVote":1,"tweetType":1,"viewCount":2336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095720288,"gmtCreate":1644999013672,"gmtModify":1676533984947,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095720288","repostId":"1116460152","repostType":4,"repost":{"id":"1116460152","kind":"news","pubTimestamp":1644974950,"share":"https://ttm.financial/m/news/1116460152?lang=en_US&edition=fundamental","pubTime":"2022-02-16 09:29","market":"us","language":"en","title":"Nio Stock Should Trade Sideways as Its Earnings Period Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=1116460152","media":"InvestorPlace","summary":"Nio(NYSE:NIO) stock has a few significant headwinds to fight off. At the same time, there are expect","content":"<div>\n<p>Nio(NYSE:NIO) stock has a few significant headwinds to fight off. At the same time, there are expectations that it should perform well when it releases earnings in March.Let’s jump right into the ...</p>\n\n<a href=\"https://investorplace.com/2022/02/nio-stock-should-trade-sideways-as-its-earnings-period-approaches/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Stock Should Trade Sideways as Its Earnings Period Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Stock Should Trade Sideways as Its Earnings Period Approaches\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 09:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/nio-stock-should-trade-sideways-as-its-earnings-period-approaches/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio(NYSE:NIO) stock has a few significant headwinds to fight off. At the same time, there are expectations that it should perform well when it releases earnings in March.Let’s jump right into the ...</p>\n\n<a href=\"https://investorplace.com/2022/02/nio-stock-should-trade-sideways-as-its-earnings-period-approaches/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2022/02/nio-stock-should-trade-sideways-as-its-earnings-period-approaches/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116460152","content_text":"Nio(NYSE:NIO) stock has a few significant headwinds to fight off. At the same time, there are expectations that it should perform well when it releases earnings in March.Let’s jump right into the positive first, and then the negative. That said, my intuition is that the negatives right now should serve to weigh Nio down for the next few weeks and beyond its March 7 earnings date.Anyway, onto the good news first.Earnings Should Be Strong for NIO StockThe positive news is that Nio should continue to perform well when it releases earnings on March 7.Early indications are that Nio will report earnings per share figures somewhere in the neighborhood of $-0.14. That negative number might not seem particularly attractive, but remember, Nio reported $-1.05 EPS in the fourth quarter (Q4) of 2020.There is reason to believe Nio should be strong otherwise. It should report roughly $5.63 billion in revenues in 2021. That number is anticipated to increase to $9.88 billion in 2022. But that is a longer term view than in the next few weeks and months. Unfortunately, Nio faces some serious headwinds in that period.For one, the pressure on tech stocks should ratchet upward drastically.Tech Woes Should IncreaseThat is true because inflation hit another 40-year high in January, reaching 7.5%. That was even higher than the 7.2%, which was anticipated.That is a particular problem for Nio stock as it is a tech stock. Tech stocks were already feeling pressure because of December’s inflation figures, which reached 7%. That, too, was a 40-year high.That rising inflation triggered mass speculation that the U.S. Federal Reserve will raise interest rates to curb inflation’s effects. Rising interest rates signal the end of easy money, which in turn causes investors to flee tech stocks.That was clearly on display as tech stocks suffered heavy losses in January on the heels of the December inflation figures release. Given that February’s numbers are even worse, expect more of the same.So, my thought is this: Nio will be weighed down by those worries as March begins. We won’t have February numbers until after Nio releases earnings on March 7. Investors are going to be hesitant to push capital into Nio even if it does report strong numbers for fear that February inflation also surprises negatively.And on top of that, Nio already had a problem with declining deliveries.Deliveries Slipped in JanuaryDecember was a strong month for Nio in terms of deliveries. It delivered 10,489 vehicles. However, January didn’t go as well for the Chineseelectric vehicle (EV)manufacturer.It delivered 9,652 vehicles in the month. While that represented 33.6% growth over the same month last year, it was a decline sequentially.It really boils down to market perception. Investors didn’t react much to the news when it was released on Feb. 1. Share prices pretty much stayed steady.What to do With NIO StockI believe that over the next few weeks, NIO stock will trade sideways at best. My belief is that the tech sector simply faces headwinds that are currently too strong. Nio remains a strong bet for the long term. I have never wavered on that opinion. EVs have proven that they are the future of automobiles. And Nio has proven that it is a leader among the future of automobiles.But the reality is that inflation is out of control right now. Whether EVs are here stay doesn’t really figure into the conversation at the moment. Consumers experienced 7% inflation in December, and 7.5% inflation in January. That hurts tech stocks in a very tangible way as January proved. February is about to get worse. And then we have to wait and see how March turns out. None of that bodes well for Nio or any other equity in the tech sector.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096770386,"gmtCreate":1644472321605,"gmtModify":1676533931253,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096770386","repostId":"2210556631","repostType":4,"repost":{"id":"2210556631","kind":"highlight","pubTimestamp":1644455674,"share":"https://ttm.financial/m/news/2210556631?lang=en_US&edition=fundamental","pubTime":"2022-02-10 09:14","market":"us","language":"en","title":"Want 140% to 225% Gains? 2 Growth Stocks to Buy, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2210556631","media":"Motley Fool","summary":"Despite a difficult macroeconomic environment, some analysts are bullish on these growth stocks.","content":"<div>\n<p>Despite the recent sell-off, the S&P 500 is still up 18% over the past year, outpacing its own long-term average of 8% annualized growth. Even so, some Wall Street analysts see plenty of upside left ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/09/want-140-to-225-gains-2-growth-stocks-to-buy/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want 140% to 225% Gains? 2 Growth Stocks to Buy, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant 140% to 225% Gains? 2 Growth Stocks to Buy, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-10 09:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/09/want-140-to-225-gains-2-growth-stocks-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the recent sell-off, the S&P 500 is still up 18% over the past year, outpacing its own long-term average of 8% annualized growth. Even so, some Wall Street analysts see plenty of upside left ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/09/want-140-to-225-gains-2-growth-stocks-to-buy/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4508":"社交媒体","BK4528":"SaaS概念","SNAP":"Snap Inc","BK4554":"元宇宙及AR概念","BK4555":"新能源车","BK4543":"AI","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4077":"互动媒体与服务","BK4527":"明星科技股","BK4548":"巴美列捷福持仓","TSLA":"特斯拉","BK4551":"寇图资本持仓","BK4099":"汽车制造商","BK4213":"石油与天然气的勘探与生产","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4023":"应用软件"},"source_url":"https://www.fool.com/investing/2022/02/09/want-140-to-225-gains-2-growth-stocks-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210556631","content_text":"Despite the recent sell-off, the S&P 500 is still up 18% over the past year, outpacing its own long-term average of 8% annualized growth. Even so, some Wall Street analysts see plenty of upside left in the market, particularly when it comes to growth stocks, many of which have fallen sharply over the last few months.For instance, Ark Invest currently has a price target of $3,000 on Tesla (NASDAQ:TSLA), implying 225% upside by 2025. And Credit Suisse raised its price target on Snap (NASDAQ:SNAP) to $93 after a strong fourth quarter, implying 140% upside in the next 12 months. Given the potential gains, is it time to add these growth stocks to your portfolio?Let's take a closer look.Image source: Tesla1. TeslaSemiconductor shortages weighed on the auto industry in 2021, but Tesla turned in another impressive performance. For the fourth consecutive year, it ranked as the world's leading electric vehicle (EV) brand, holding 14.4% market share. And the company grew its deliveries by 87%, outpacing all other high-volume manufacturers for the thirteenth consecutive quarter.Perhaps more important, Tesla's efforts to make manufacturing more efficient -- boosting production in California and China, single-piece casting for the Model Y -- are paying off. In the third quarter, the company posted an industry-leading operating margin of 14.6%, and that figure ticked up to 14.7% in the fourth quarter. Additionally, the cost of goods per vehicle dropped to $36,000 in the fourth quarter, down from $38,000 in the first quarter and $84,000 in 2017.For the full year, Tesla's revenue skyrocketed 71% to $53.8 billion, and the company posted a GAAP profit of $2.05 per diluted share -- in fact, the company has now achieved GAAP profitability for the last 10 consecutive quarters. And free cash flow jumped 49% to $2.8 billion. More importantly, the future looks bright for Tesla, as the company believes it can grow EV deliveries at least 50% per year over a multi-year horizon. And output should improve in 2022 as the new Gigafactories in Berlin and Texas start producing vehicles.Perhaps more exciting, CEO Elon Musk noted that Tesla's full self-driving software would eventually be its greatest source of profitability, and he also said the company would \"achieve full self-driving this year.\" If that does indeed come to pass, Tesla would able to launch an autonomous ride-sharing platform, pioneering a market that ARK Invest values at $1.2 trillion by 2030.Also noteworthy, Musk said Tesla's AI-powered humanoid robot (Optimus) may enter production in 2023 -- along with the Cybertruck and Semi -- and that Optimus could eventually be bigger than Tesla's automotive business.So could Tesla reach $3,000 per share by 2025? Well, that would put its market cap at $3 trillion, which is no small task. But if Tesla continues to execute on EV production, while also delivering on its promise of an autonomous ride-sharing service, I think it could hit that price target. But even if that doesn't happen, Tesla still looks like a good stock to hold for the long term.Image source: Getty Images.2. SnapSnap is a camera company that specializes in augmented reality (AR) and artificial intelligence (AI). Its core product is Snapchat, a social platform designed for visual communication. Specifically, people can personalize photos and videos with AR lenses -- tools that add 3D objects and special effects -- then share that content with friends, families, and the broader Snapchat community.Snap's camera also supports scanning, a feature that leans on AI to understand what the camera sees in the viewfinder. For instance, you can scan a car to learn more about the make and model, or you could scan a household product to purchase it on Amazon's marketplace. In short, Snap uses AR and AI to create an engaging social experience, and that strategy has made the mobile app particularly popular with younger generations.In fact, 75% of 13-to-34-year-olds in the United States use Snapchat, and the same is true in geographies like the United Kingdom, France, and Australia. That demographic is particularly valuable to advertisers, as it gives them a chance to build long-lasting customer relationships. To that end, Snap monetizes its business by helping brands build, measure, and optimize targeted ad campaigns.For the full year, the company delivered impressive financial results. Revenue soared 64% to $4.1 billion, and while Snap is still unprofitable on a GAAP basis, the loss narrowed to $488 million in 2021. Better yet, the company posted free cash flow of $223 million, marking the first time Snap has generated positive free cash flow on a full-year basis.So could Snap hit $93 per share in the next 12 months? It's certainly possible, assuming the company continues to execute and Wall Street reacquires its taste for richly valued growth stocks. But even if that doesn't happen, I think this stock looks like a smart long-term investment, as it taps into high-growth industries like digital advertising and the metaverse.","news_type":1,"symbols_score_info":{"SNAP":0,"TSLA":0}},"isVote":1,"tweetType":1,"viewCount":3392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096979260,"gmtCreate":1644289326289,"gmtModify":1676533909130,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096979260","repostId":"1194812135","repostType":4,"isVote":1,"tweetType":1,"viewCount":3411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096000912,"gmtCreate":1644245764817,"gmtModify":1676533903935,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096000912","repostId":"1148872178","repostType":2,"repost":{"id":"1148872178","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644245596,"share":"https://ttm.financial/m/news/1148872178?lang=en_US&edition=fundamental","pubTime":"2022-02-07 22:53","market":"us","language":"en","title":"Some Blockchain Stocks Soared in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148872178","media":"Tiger Newspress","summary":"Some Blockchain Stocks soared in morning trading. SOS Ltd, Riot Blockchain, Marathon Digital, Bit Di","content":"<html><head></head><body><p>Some Blockchain Stocks soared in morning trading. <a href=\"https://laohu8.com/S/SOS\">SOS Ltd</a>, <a href=\"https://laohu8.com/S/RIOT\">Riot Blockchain</a>, <a href=\"https://laohu8.com/S/MARA\">Marathon Digital</a>, <a href=\"https://laohu8.com/S/BTBT\">Bit Digital</a>, <a href=\"https://laohu8.com/S/COIN\">Coinbase</a> and <a href=\"https://laohu8.com/S/CAN\">Canaan</a> rose between 5% and 12%.</p><p><img src=\"https://static.tigerbbs.com/f7ac7622747b6d0ca7dae5ba0e2aa7e7\" tg-width=\"412\" tg-height=\"530\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Blockchain Stocks Soared in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Blockchain Stocks Soared in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-07 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some Blockchain Stocks soared in morning trading. <a href=\"https://laohu8.com/S/SOS\">SOS Ltd</a>, <a href=\"https://laohu8.com/S/RIOT\">Riot Blockchain</a>, <a href=\"https://laohu8.com/S/MARA\">Marathon Digital</a>, <a href=\"https://laohu8.com/S/BTBT\">Bit Digital</a>, <a href=\"https://laohu8.com/S/COIN\">Coinbase</a> and <a href=\"https://laohu8.com/S/CAN\">Canaan</a> rose between 5% and 12%.</p><p><img src=\"https://static.tigerbbs.com/f7ac7622747b6d0ca7dae5ba0e2aa7e7\" tg-width=\"412\" tg-height=\"530\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOS":"SOS Limited","BTBT":"Bit Digital, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148872178","content_text":"Some Blockchain Stocks soared in morning trading. SOS Ltd, Riot Blockchain, Marathon Digital, Bit Digital, Coinbase and Canaan rose between 5% and 12%.","news_type":1,"symbols_score_info":{"SOS":0.9,"BTBT":0.9}},"isVote":1,"tweetType":1,"viewCount":3996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098644446,"gmtCreate":1644122964133,"gmtModify":1676533892699,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098644446","repostId":"2208317024","repostType":4,"repost":{"id":"2208317024","kind":"highlight","pubTimestamp":1644039774,"share":"https://ttm.financial/m/news/2208317024?lang=en_US&edition=fundamental","pubTime":"2022-02-05 13:42","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $1,000 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2208317024","media":"Motley Fool","summary":"These outstanding companies have the potential to generate market-crushing returns.","content":"<div>\n<p>The S&P 500 has had a cold start to the new year, down 6% in the month of January. This situation might be scaring investors out of the market entirely, as the downward trend could continue with ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/3-no-brainer-stocks-to-buy-with-1000-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $1,000 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $1,000 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 13:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/04/3-no-brainer-stocks-to-buy-with-1000-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 has had a cold start to the new year, down 6% in the month of January. This situation might be scaring investors out of the market entirely, as the downward trend could continue with ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/04/3-no-brainer-stocks-to-buy-with-1000-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","PYPL":"PayPal","BK4524":"宅经济概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4527":"明星科技股","BK4534":"瑞士信贷持仓","BK4503":"景林资产持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4122":"互联网与直销零售","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4106":"数据处理与外包服务","LULU":"lululemon athletica","BK4504":"桥水持仓","BK4559":"巴菲特持仓","AMZN":"亚马逊","BK4538":"云计算","BK4108":"电影和娱乐","BK4550":"红杉资本持仓","BK4507":"流媒体概念","BK4202":"服装、服饰与奢侈品","BK4548":"巴美列捷福持仓","NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2022/02/04/3-no-brainer-stocks-to-buy-with-1000-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208317024","content_text":"The S&P 500 has had a cold start to the new year, down 6% in the month of January. This situation might be scaring investors out of the market entirely, as the downward trend could continue with uncertainty about inflation, the Fed's pending rate hikes, and the ongoing pandemic adding to the worries. But if you're an investor with a long time horizon, like me, then now could be the perfect time to add fresh capital to your portfolio. When the market seems overly pessimistic and full of fear is usually the best time to be aggressive. With $1,000 to invest, look no further than Lululemon (NASDAQ:LULU), Netflix (NASDAQ:NFLX), and PayPal (NASDAQ:PYPL) as worthy additions to your portfolio. Image source: Getty Images.1. Lululemon Since February 2017, Lululemon's stock has soared 390%, an outstanding investment if you got in at that time. This performance can be attributed to Lululemon's impressive sales and profit growth of 166% and 175%, respectively, over the past five years. Expanding the store footprint, now at 552 locations, also helped. This burgeoning apparel brand sports a better gross margin, at 57.2%, than industry leader Nike. A higher metric generally indicates customers' propensity to pay premium prices for a company's products. In Lululemon's case, having a strong direct-to-consumer presence -- a channel that represented 40% of sales in the most recent quarter -- is crucial for brand relevance. The business first gained popularity as a seller of yoga pants to women, but it has now become a major men's outfitter. The men's segment increased revenue 44% year over year in the fiscal 2021 third quarter, while the women's segment grew 25%. Diversification of revenue sources is a positive sign. Lululemon shares have lost 30% in value over the past three months as the threat of higher interest rates negatively impacts high-multiple, high-growth stocks. Consequently, investors are presented with a great opportunity to buy shares in this thriving retailer at a meaningful pullback. 2. Netflix This top streaming stock reported fourth-quarter 2021 financial results on Jan. 20 that disappointed investors. Management guided to 2.5 million net new subscribers in the current quarter, far less than the 6.9 million Wall Street was expecting. But despite the stock being down 17% since that announcement, Netflix has been a massive winner, rising 200% over the past five years. Quarterly membership growth has certainly been irregular and unpredictable after the pandemic started in the spring of 2020, but the secular shift away from traditional cable TV and toward streaming is not going away. According to data from S&P Global, there were 1.1 billion households worldwide with a cable TV subscription in 2020. This means that Netflix, with its 221.8 million customers today, still has a large runway for expansion in the years ahead.  Billionaire hedge fund manager Bill Ackman, through his firm Pershing Square Capital Management, took advantage of the market souring on Netflix by scooping up 3.1 million shares. His firm is now a top-20 shareholder in the company. Ackman has a proven track record of pouncing on attractive investment opportunities when the time is right. That's a great endorsement for why you might want to consider owning Netflix stock as well.  3. PayPalAnother major historical winner is fintech behemoth PayPal. Its stock has climbed 379% since the business was spun off from eBay in July 2015. PayPal has long been a pioneer in the digital payments space, and it now counts an impressive 426 million active accounts, of which 34 million are merchants. I think there are three main factors that make PayPal a special business. For starters, the company's brand exemplifies a relentless focus on security and ease of use. These characteristics, along with massive scale to the tune of $1.25 trillion in total payment volume in 2021, are probably why e-commerce giant Amazon chose to partner with PayPal's Venmo starting this year. Additionally, PayPal possesses remarkable financial metrics. In 2021, the company's non-generally accepted accounting principles (GAAP) operating margin of 24.8% was stellar. And the business continued to prove that it's a cash machine, generating $5.4 billion in free cash flow during the 12-month period. Lastly, the company is not done growing. Along with the Amazon partnership, initiatives to bolster the PayPal mobile app and an acquisition like that of Japanese buy now, pay later specialist Paidy showcase management's huge ambition to one day have 1 billion daily active users. PayPal's shares are off more than 50% from their recent high set in July 2021. The stock currently trades for a lower and more attractive price-to-earnings (P/E) ratio of below 40, making it a solid investment right now.","news_type":1,"symbols_score_info":{"PYPL":1,"AMZN":0.81,"NFLX":0.6,"LULU":1}},"isVote":1,"tweetType":1,"viewCount":3230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093306309,"gmtCreate":1643509767814,"gmtModify":1676533827038,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093306309","repostId":"1175006642","repostType":4,"repost":{"id":"1175006642","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643380672,"share":"https://ttm.financial/m/news/1175006642?lang=en_US&edition=fundamental","pubTime":"2022-01-28 22:37","market":"us","language":"en","title":"EV Stocks Dropped in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1175006642","media":"Tiger Newspress","summary":"EV stocks dropped in morning trading, with Tesla falling over 1% and Lucid falling over 6%.","content":"<html><head></head><body><p>EV stocks dropped in morning trading, with Tesla falling over 1% and Lucid falling over 6%.<img src=\"https://static.tigerbbs.com/9429830fb306e011c657a75260c129d3\" tg-width=\"365\" tg-height=\"471\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks Dropped in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks Dropped in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-28 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>EV stocks dropped in morning trading, with Tesla falling over 1% and Lucid falling over 6%.<img src=\"https://static.tigerbbs.com/9429830fb306e011c657a75260c129d3\" tg-width=\"365\" tg-height=\"471\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","LCID":"Lucid Group Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175006642","content_text":"EV stocks dropped in morning trading, with Tesla falling over 1% and Lucid falling over 6%.","news_type":1,"symbols_score_info":{"LCID":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":4171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093308404,"gmtCreate":1643509710964,"gmtModify":1676533827070,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"themes":[],"htmlText":"please like","listText":"please like","text":"please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093308404","repostId":"1157223555","repostType":4,"repost":{"id":"1157223555","kind":"news","pubTimestamp":1643443466,"share":"https://ttm.financial/m/news/1157223555?lang=en_US&edition=fundamental","pubTime":"2022-01-29 16:04","market":"us","language":"en","title":"Goldman Sachs Predicts Fed Will Raise Rates Five Times This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1157223555","media":"Bloomberg","summary":"Goldman Sachs Group Inc.’s economists joined Wall Street peers in forecasting the Federal Reserve wi","content":"<html><head></head><body><p>Goldman Sachs Group Inc.’s economists joined Wall Street peers in forecasting the Federal Reserve will raise interest rates more aggressively than they previously expected.</p><p>Economists led by Jan Hatzius now predict the Fed will lift its near zero benchmark by 25 basis points five times this year rather than on four occasions. That would take the benchmark to 1.25%-1.5% by the end of the year.</p><p>Shifts are now seen by Goldman Sachs in March, May, July, September and December. They also expect officials to announce the start of a balance sheet reduction in June.</p><p>The switch came days after Fed Chair Jerome Powell said officials were ready to raise rates in March and left the door open to moving at every meeting if needed to curb the fastest inflation in 40 years. A government report on Friday showed the Employment Cost Index rose 4% in the year through December, the most in two decades.</p><p>Fed Kicks Off Most Aggressive Global Tightening in Decades</p><p>“The evidence that wage growth is running above levels consistent with the Fed’s inflation target has strengthened, and we have revised up our inflation path,” the Goldman Sachs economists said in a report to clients. “In addition, Chair Powell’s comments earlier this week made it clear that the Fed leadership is open to a more aggressive pace of tightening.”</p><p>The Fed could still switch gears if market conditions change or the economy decelerates much faster than projected, or tighten monetary policy even more than forecast if inflation remains high enough, they said.</p><p>Even as they agreed the Fed will do more than they previously bet, banks were divided this week over how aggressive policy makers would be.</p><p>Bank of America Corp. now predicts seven rate hikes in 2022 and BNP Paribas SA forecasts six, while JPMorgan Chase &amp; Co. and Deutsche Bank AG see five.</p><p>Nomura Holdings Inc. even reckons the central bank will deliver a 50 basis points increase in March, which would be the biggest move since 2000.</p><p>Bloomberg Economics is sticking with the projection of five hikes it made earlier this month, though Chief Economist Anna Wong said this week there is a risk of six increases.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Predicts Fed Will Raise Rates Five Times This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Predicts Fed Will Raise Rates Five Times This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-29 16:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/goldman-sachs-predicts-fed-raise-071350897.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Goldman Sachs Group Inc.’s economists joined Wall Street peers in forecasting the Federal Reserve will raise interest rates more aggressively than they previously expected.Economists led by Jan ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-predicts-fed-raise-071350897.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/goldman-sachs-predicts-fed-raise-071350897.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157223555","content_text":"Goldman Sachs Group Inc.’s economists joined Wall Street peers in forecasting the Federal Reserve will raise interest rates more aggressively than they previously expected.Economists led by Jan Hatzius now predict the Fed will lift its near zero benchmark by 25 basis points five times this year rather than on four occasions. That would take the benchmark to 1.25%-1.5% by the end of the year.Shifts are now seen by Goldman Sachs in March, May, July, September and December. They also expect officials to announce the start of a balance sheet reduction in June.The switch came days after Fed Chair Jerome Powell said officials were ready to raise rates in March and left the door open to moving at every meeting if needed to curb the fastest inflation in 40 years. A government report on Friday showed the Employment Cost Index rose 4% in the year through December, the most in two decades.Fed Kicks Off Most Aggressive Global Tightening in Decades“The evidence that wage growth is running above levels consistent with the Fed’s inflation target has strengthened, and we have revised up our inflation path,” the Goldman Sachs economists said in a report to clients. “In addition, Chair Powell’s comments earlier this week made it clear that the Fed leadership is open to a more aggressive pace of tightening.”The Fed could still switch gears if market conditions change or the economy decelerates much faster than projected, or tighten monetary policy even more than forecast if inflation remains high enough, they said.Even as they agreed the Fed will do more than they previously bet, banks were divided this week over how aggressive policy makers would be.Bank of America Corp. now predicts seven rate hikes in 2022 and BNP Paribas SA forecasts six, while JPMorgan Chase & Co. and Deutsche Bank AG see five.Nomura Holdings Inc. even reckons the central bank will deliver a 50 basis points increase in March, which would be the biggest move since 2000.Bloomberg Economics is sticking with the projection of five hikes it made earlier this month, though Chief Economist Anna Wong said this week there is a risk of six increases.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":100860279,"gmtCreate":1619600321291,"gmtModify":1704726588089,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment pls","listText":"like and comment pls","text":"like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":8,"repostSize":0,"link":"https://ttm.financial/post/100860279","repostId":"1131068131","repostType":4,"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561335246727315","authorId":"3561335246727315","name":"Chriz","avatar":"https://static.tigerbbs.com/8c393b32112334e204b0590fb83bbc7d","crmLevel":2,"crmLevelSwitch":0,"idStr":"3561335246727315","authorIdStr":"3561335246727315"},"content":"reply pls","text":"reply pls","html":"reply pls"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":455154164687104,"gmtCreate":1752130153512,"gmtModify":1752130156136,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ITRM\">$Iterum Therapeutics Plc(ITRM)$</a> 🎸🚀🙌🏼🎁🎰","listText":"<a href=\"https://ttm.financial/S/ITRM\">$Iterum Therapeutics Plc(ITRM)$</a> 🎸🚀🙌🏼🎁🎰","text":"$Iterum Therapeutics Plc(ITRM)$ 🎸🚀🙌🏼🎁🎰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/455154164687104","isVote":1,"tweetType":1,"viewCount":1792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146962457,"gmtCreate":1626050069379,"gmtModify":1703752273879,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment ty","listText":"like and comment ty","text":"like and comment ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/146962457","repostId":"1114863871","repostType":4,"repost":{"id":"1114863871","kind":"news","pubTimestamp":1626039626,"share":"https://ttm.financial/m/news/1114863871?lang=en_US&edition=fundamental","pubTime":"2021-07-12 05:40","market":"us","language":"en","title":"Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1114863871","media":"Barron's","summary":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% a","content":"<p>Second-quarter earnings season gets under way&nbsp;this week, with several big banks reporting.&nbsp;JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.</p>\n<p>Other major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.</p>\n<p>The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday,&nbsp;followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.</p>\n<p>Investors and economists will also get a look at a pair of sentiment surveys this week:&nbsp;The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The&nbsp;Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.</p>\n<p><img src=\"https://static.tigerbbs.com/1508a89eaa3fb959feaaa832797a2c48\" tg-width=\"1176\" tg-height=\"360\"></p>\n<p><b>Monday 7/12</b></p>\n<p>FedExhosts a conference call to update the investment community on its business outlook.</p>\n<p><b>Tuesday 7/13</b></p>\n<p>JPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.</p>\n<p>Conagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.</p>\n<p>Dell Technologieshosts a conference call to discuss its ESG strategy.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.</p>\n<p><b>The National Federation</b>&nbsp;of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.</p>\n<p><b>Wednesday 7/14</b></p>\n<p>Bank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.</p>\n<p><b>The Federal Reserve</b>&nbsp;releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.</p>\n<p><b>The BLS releases</b>&nbsp;the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.</p>\n<p><b>Thursday 7/15</b></p>\n<p>Bank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.</p>\n<p><b>Friday 7/16</b></p>\n<p>Charles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.</p>\n<p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.</p>\n<p><b>The University of Michigan</b>&nbsp;releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.</p>\n<p><b>The Census Bureau</b>&nbsp;reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 05:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","BAC":"美国银行","MS":"摩根士丹利","JPM":"摩根大通","TSM":"台积电","C":"花旗","WFC":"富国银行"},"source_url":"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114863871","content_text":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.\nOther major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.\nThe week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.\nInvestors and economists will also get a look at a pair of sentiment surveys this week: The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.\n\nMonday 7/12\nFedExhosts a conference call to update the investment community on its business outlook.\nTuesday 7/13\nJPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.\nConagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.\nDell Technologieshosts a conference call to discuss its ESG strategy.\nThe Bureau of Labor Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.\nThe National Federation of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.\nWednesday 7/14\nBank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.\nThe Federal Reserve releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.\nThe BLS releases the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.\nThursday 7/15\nBank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.\nFriday 7/16\nCharles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.\nThe Bank of Japan announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.\nThe University of Michigan releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.\nThe Census Bureau reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.","news_type":1,"symbols_score_info":{"C":0.9,"TSM":0.9,"BAC":0.9,"WFC":0.9,"MS":0.9,"JPM":0.9,"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":702,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180264133,"gmtCreate":1623206928322,"gmtModify":1704198361500,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment ty","listText":"like and comment ty","text":"like and comment ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/180264133","repostId":"1128909306","repostType":4,"repost":{"id":"1128909306","kind":"news","pubTimestamp":1623193560,"share":"https://ttm.financial/m/news/1128909306?lang=en_US&edition=fundamental","pubTime":"2021-06-09 07:06","market":"us","language":"en","title":"S&P 500 closes little changed as \"meme stocks\" extend rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1128909306","media":"reuters","summary":"NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of c","content":"<p>NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the ongoing meme stocks rally.</p><p>All three major U.S. stock indexes ended the range-bound session near flat or higher, with the S&amp;P 500 and the Dow closing within about 0.5% of record highs.</p><p>The tech-laded Nasdaq Composite fared best, with Amazon.com Inc and Apple Inc providing the biggest boost.</p><p>“We’re waiting for inflation numbers, waiting for more from the (Federal Reserve), waiting for earnings season,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “There’s not a lot motivating the market today.”</p><p>“We’re in this twilight zone until probably right after the Fourth of July, when we see earnings season kick in,” Nolte added.</p><p>The CBOE volatility index, a measure of investor anxiety, touched its lowest level in over a year.</p><p>Smallcaps, once again buoyed by the ongoing meme stock retail frenzy, were outperforming their larger counterparts.</p><p>Clover Health Investments seized top billing among meme stocks, surging 85.8%, the biggest percentage winner in the Nasdaq.</p><p>Other stocks whose recent explosive trading volumes have been attributed to social media buzz, including GameStop Corp, Bed Bath &amp; Beyond Inc, Workhorse Group and others, ended the session between 7% and 12% higher.</p><p>“(Meme stocks) are where the action is, but you flip it over and look crypto and that’s a mess,” Nolte said. “Now the meme stocks are taking over from crypto as the place to be and it’s all a consequence of very easy monetary policy.”</p><p>Reports from the U.S. Labor Department and National Federation of Independent Business appeared to confirm a labor shortage even as demand roars back to life, which could put upward pressure on wages, a precursor to wider inflation.</p><p>Market participants look to Thursday’s consumer price index data for further clues regarding inflation, and how it could influence the Federal Reserve’s timetable for tightening its monetary policy.</p><p>The Dow Jones Industrial Average fell 30.42 points, or 0.09%, to 34,599.82; the S&amp;P 500 gained 0.74 points, or 0.02%, at 4,227.26; and the Nasdaq Composite added 43.19 points, or 0.31%, at 13,924.91.</p><p>Of the 11 major sectors in the S&amp;P 500, consumer discretionary enjoyed the biggest percentage gain, and utilities suffered the largest loss.</p><p>Sales of Tesla Inc’s China-made electric cars jumped in May by 29%, marking a 177% year-on-year increase, according to the China Passenger Car Association. The stock erased initial gains on the news to close down 0.3%.</p><p>Boeing Co shares were boosted by Southwest Airlines’ announcement that it had ordered 34 new 737 MAX aircraft, but the planemaker’s shares pared gains to end the session flat.</p><p>GameStop, the company most closely associated with the Reddit-driven short squeeze phenomenon, is expected to report quarterly results after markets close on Wednesday.</p><p>Advancing issues outnumbered decliners on the NYSE by a 1.74-to-1 ratio; on Nasdaq, a 1.66-to-1 ratio favored advancers.</p><p>The S&amp;P 500 posted 54 new 52-week highs and one new low; the Nasdaq Composite recorded 172 new highs and 16 new lows.</p><p>Volume on U.S. exchanges was 11.82 billion shares, compared with the 10.75 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 closes little changed as \"meme stocks\" extend rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 closes little changed as \"meme stocks\" extend rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 07:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","CLOV":"Clover Health Corp"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-closes-little-changed-as-meme-stocks-extend-rally-idUSL2N2NQ2NX","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128909306","content_text":"NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of clear market catalysts kept institutional investors on the sidelines, while retail traders fueled the ongoing meme stocks rally.All three major U.S. stock indexes ended the range-bound session near flat or higher, with the S&P 500 and the Dow closing within about 0.5% of record highs.The tech-laded Nasdaq Composite fared best, with Amazon.com Inc and Apple Inc providing the biggest boost.“We’re waiting for inflation numbers, waiting for more from the (Federal Reserve), waiting for earnings season,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “There’s not a lot motivating the market today.”“We’re in this twilight zone until probably right after the Fourth of July, when we see earnings season kick in,” Nolte added.The CBOE volatility index, a measure of investor anxiety, touched its lowest level in over a year.Smallcaps, once again buoyed by the ongoing meme stock retail frenzy, were outperforming their larger counterparts.Clover Health Investments seized top billing among meme stocks, surging 85.8%, the biggest percentage winner in the Nasdaq.Other stocks whose recent explosive trading volumes have been attributed to social media buzz, including GameStop Corp, Bed Bath & Beyond Inc, Workhorse Group and others, ended the session between 7% and 12% higher.“(Meme stocks) are where the action is, but you flip it over and look crypto and that’s a mess,” Nolte said. “Now the meme stocks are taking over from crypto as the place to be and it’s all a consequence of very easy monetary policy.”Reports from the U.S. Labor Department and National Federation of Independent Business appeared to confirm a labor shortage even as demand roars back to life, which could put upward pressure on wages, a precursor to wider inflation.Market participants look to Thursday’s consumer price index data for further clues regarding inflation, and how it could influence the Federal Reserve’s timetable for tightening its monetary policy.The Dow Jones Industrial Average fell 30.42 points, or 0.09%, to 34,599.82; the S&P 500 gained 0.74 points, or 0.02%, at 4,227.26; and the Nasdaq Composite added 43.19 points, or 0.31%, at 13,924.91.Of the 11 major sectors in the S&P 500, consumer discretionary enjoyed the biggest percentage gain, and utilities suffered the largest loss.Sales of Tesla Inc’s China-made electric cars jumped in May by 29%, marking a 177% year-on-year increase, according to the China Passenger Car Association. The stock erased initial gains on the news to close down 0.3%.Boeing Co shares were boosted by Southwest Airlines’ announcement that it had ordered 34 new 737 MAX aircraft, but the planemaker’s shares pared gains to end the session flat.GameStop, the company most closely associated with the Reddit-driven short squeeze phenomenon, is expected to report quarterly results after markets close on Wednesday.Advancing issues outnumbered decliners on the NYSE by a 1.74-to-1 ratio; on Nasdaq, a 1.66-to-1 ratio favored advancers.The S&P 500 posted 54 new 52-week highs and one new low; the Nasdaq Composite recorded 172 new highs and 16 new lows.Volume on U.S. exchanges was 11.82 billion shares, compared with the 10.75 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,"CLOV":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":888,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3580291159442629","authorId":"3580291159442629","name":"pxgcess","avatar":"https://static.tigerbbs.com/3eb9eb42fe007c4bd0c4331c7ac05dc9","crmLevel":1,"crmLevelSwitch":0,"idStr":"3580291159442629","authorIdStr":"3580291159442629"},"content":"Reply to my comment pls!","text":"Reply to my comment pls!","html":"Reply to my comment pls!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143284676,"gmtCreate":1625796179495,"gmtModify":1703748719179,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment pls","listText":"like and comment pls","text":"like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/143284676","repostId":"1195657546","repostType":4,"isVote":1,"tweetType":1,"viewCount":943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183035359,"gmtCreate":1623293021971,"gmtModify":1704200244921,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment ty","listText":"like and comment ty","text":"like and comment ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/183035359","repostId":"1142408805","repostType":4,"repost":{"id":"1142408805","kind":"news","pubTimestamp":1623280126,"share":"https://ttm.financial/m/news/1142408805?lang=en_US&edition=fundamental","pubTime":"2021-06-10 07:08","market":"us","language":"en","title":"U.S. stocks end lower ahead of inflation report","url":"https://stock-news.laohu8.com/highlight/detail?id=1142408805","media":"reuters","summary":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants a","content":"<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.</p>\n<p>The retail “meme stock” craze continued unabated.</p>\n<p>All three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.</p>\n<p>“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”</p>\n<p>Heavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.</p>\n<p>Reddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.</p>\n<p>However, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath &amp; Beyond closed lower.</p>\n<p>Retail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.</p>\n<p>“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”</p>\n<p>“I don’t think you should read too much regarding the broader market.”</p>\n<p>GameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.</p>\n<p>U.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.</p>\n<p>Industrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.</p>\n<p>Washington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.</p>\n<p>Even so, the Philadelphia SE Semiconductor index slipped 0.4%.</p>\n<p>The Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.</p>\n<p>The Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&amp;P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare gained the most.</p>\n<p>Benchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.</p>\n<p>Campbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.</p>\n<p>Drugmaker Merck &amp; Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.</p>\n<p>Declining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.</p>\n<p>Volume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks end lower ahead of inflation report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks end lower ahead of inflation report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","AEMD":"Aethlon Medical Inc",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142408805","content_text":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.\nThe retail “meme stock” craze continued unabated.\nAll three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.\n“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”\nHeavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.\nReddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.\nHowever, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath & Beyond closed lower.\nRetail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.\n“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”\n“I don’t think you should read too much regarding the broader market.”\nGameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.\nU.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.\nIndustrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.\nWashington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.\nEven so, the Philadelphia SE Semiconductor index slipped 0.4%.\nThe Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.\nThe Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.\nAmong the 11 major sectors in the S&P 500, healthcare gained the most.\nBenchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.\nCampbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.\nDrugmaker Merck & Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.\nDeclining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.\nThe S&P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.\nVolume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".IXIC":0.9,"AEMD":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001017498,"gmtCreate":1641102546379,"gmtModify":1676533572829,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like please","listText":"like please","text":"like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001017498","repostId":"2200441314","repostType":4,"repost":{"id":"2200441314","kind":"highlight","pubTimestamp":1641085740,"share":"https://ttm.financial/m/news/2200441314?lang=en_US&edition=fundamental","pubTime":"2022-01-02 09:09","market":"us","language":"en","title":"2 No-Brainer Stocks Down 27% to 35% to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2200441314","media":"Motley Fool","summary":"These hot tech stocks might be a steal at these prices.","content":"<div>\n<p>While the stock market at large is hitting all-time highs, many technology stocks have been getting hammered in 2021. Despite this broad drop in tech companies, many businesses are seeing strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/2-no-brainer-stocks-down-27-to-35-to-buy-for-2022/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 No-Brainer Stocks Down 27% to 35% to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 No-Brainer Stocks Down 27% to 35% to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-02 09:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/01/2-no-brainer-stocks-down-27-to-35-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While the stock market at large is hitting all-time highs, many technology stocks have been getting hammered in 2021. Despite this broad drop in tech companies, many businesses are seeing strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/2-no-brainer-stocks-down-27-to-35-to-buy-for-2022/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","TWLO":"Twilio Inc","BK4116":"互联网服务与基础架构","BK4561":"索罗斯持仓","BK4539":"次新股","BK4528":"SaaS概念","BK4548":"巴美列捷福持仓","BK4097":"系统软件","BK4505":"高瓴资本持仓","PATH":"UiPath"},"source_url":"https://www.fool.com/investing/2022/01/01/2-no-brainer-stocks-down-27-to-35-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2200441314","content_text":"While the stock market at large is hitting all-time highs, many technology stocks have been getting hammered in 2021. Despite this broad drop in tech companies, many businesses are seeing strong success operationally. The share prices are sinking, but these companies continue to grow their top-line and establish their leadership roles in their respective industries.Both UiPath (NYSE:PATH) and Twilio (NYSE:TWLO) are in this boat. Shares of both tech stocks have fallen 35% and nearly 30%, respectively, despite strong growth across their businesses. With large markets ahead of them, I think today's prices could be optimal buying opportunities to get these innovative stocks at a bargain.Image source: Getty Images.1. UiPath: Bringing AI to the enterpriseWe have all been doing something so tedious and repetitive at work that we wish we could simply have it magically completed. It is, after all, a huge waste of our time because we would rather work on more thought-intensive, engaging work. With artificial intelligence-powered virtual bots, UiPath is turning our wishes into commands.The company offers automation software that can emulate a human by understanding what is on a screen, extracting data, and making critical decisions. However, this software can do it much faster than humans, making 58% fewer mistakes. UiPath uses robotic process automation (RPA) in tandem with humans to make businesses more efficient. With UiPath, real workers are not fired or eliminated but rather freed to work on more critical tasks. UiPath has saved some of its customers millions of hours and dollars, which is why over 9,600 customers use UiPath and are currently spending 44% more than they did one year ago.The stock has not fallen because of bad operational performance. The company has brought in $602.5 million in revenue so far this year, 50% higher than the year-ago period. Shares have taken a downturn because of the major uptick in the company's net loss. In the third quarter, the company lost almost $123 million -- more than the total net loss for the first nine months of 2020. This has been because UiPath has rapidly ramped up its spending on advertising, along with research and development.This is not without good reason, however. The company projects that its addressable market will nearly double to $30 billion by 2024. UiPath is already the industry leader in RPA, according to Gartner's Magic Quadrant, but the company is ramping up spending to make sure its competitors like Automation Anywhere do not overtake them. With the RPA market growing so rapidly over the next few years, UiPath is spending now -- rather successfully -- to obtain brand recognition as the industry begins to explode.Here's the bottom line: UiPath is the leader in a futuristic industry that is expected to grow rapidly over the next few years. With so much investment going toward capturing this growth, along with a dominant product that has caught the eyes of NASA and Alphabet, I think that today's share prices are a gift to long-term investors.2. Twilio: Falling victim to the tech sell-offWith over 250,000 businesses using Twilio, most of us have used its technology without even recognizing it. Anyone who has ever communicated with a food delivery driver or Lyft driver has used Twilio's services unknowingly. The company is helping other enterprises communicate within apps, allowing consumers and businesses to connect easier. These services seem to have grown even more important for Twilio's users as they are now spending 31% more today than they did one year ago with the company.Twilio posted year-over-year revenue growth of 65% in Q3, but some of that came from its acquisitions. Although the company has consistently been able to post impressive organic growth -- something most growth-by-acquisition companies lack. In Q3, the company's revenue improved 38% year over year organically, and it has been able to organically boost its top line by 34% or more year over year for the past nine quarters.Shares have largely been sent downward in 2021, and Twilio's major net losses haven't been helping. The company lost $224 million in Q3, with almost $170 million of that being stock-based compensation. While this might be worrisome today, it is overshadowed by the impressive top-line growth that the company is seeing, both organically and inorganically, in this lucrative market. At 17 times sales, this stock is trading at levels not seen since mid-2020, leaving an opportunistic window for investors.The use of in-app communication will only become more prevalent as the world continues to adopt these habits, and Twilio has been and will likely continue benefiting from it. Twilio's future is bright, which is why I think investors should consider taking advantage of these low stock prices today.","news_type":1,"symbols_score_info":{"PATH":1,"TWLO":1}},"isVote":1,"tweetType":1,"viewCount":712,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882342593,"gmtCreate":1631664055812,"gmtModify":1676530602143,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/882342593","repostId":"1132829556","repostType":4,"repost":{"id":"1132829556","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631633374,"share":"https://ttm.financial/m/news/1132829556?lang=en_US&edition=fundamental","pubTime":"2021-09-14 23:29","market":"us","language":"en","title":"ASML shares rose more than 2% to a record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1132829556","media":"Tiger Newspress","summary":"ASML shares rose more than 2% to a record high.\n\nASML Holding is a Dutch multinational company speci","content":"<p>ASML shares rose more than 2% to a record high.</p>\n<p><img src=\"https://static.tigerbbs.com/cd6348a23222a85407f86801d5c1403f\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>ASML Holding&nbsp;is a Dutch multinational company specializing in developing, producing, and maintaining photolithography machines. ASML is a major supplier to the semiconductor industry. The firm offers chipmakers with hardware, software, and services for mass-producing microchips. ASML works to develop more affordable, more powerful, and more energy-efficient microchips. ASML contributes to ground-breaking science that solves some of humanity's most pressing issues, such as healthcare, energy use and conservation, mobility, and agriculture. The semiconductor industry has been on a tear lately due to the shortage, lifting ASML to elevated levels.</p>\n<p>ASML has benefited greatly from an increased emphasis on digitization among developed nations.</p>\n<p>The recent repurchase creates an asymmetric risk-reward opportunity.</p>\n<p>The valuation is quite high but the company's impressive growth prospects justify the premium.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASML shares rose more than 2% to a record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASML shares rose more than 2% to a record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASML shares rose more than 2% to a record high.</p>\n<p><img src=\"https://static.tigerbbs.com/cd6348a23222a85407f86801d5c1403f\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>ASML Holding&nbsp;is a Dutch multinational company specializing in developing, producing, and maintaining photolithography machines. ASML is a major supplier to the semiconductor industry. The firm offers chipmakers with hardware, software, and services for mass-producing microchips. ASML works to develop more affordable, more powerful, and more energy-efficient microchips. ASML contributes to ground-breaking science that solves some of humanity's most pressing issues, such as healthcare, energy use and conservation, mobility, and agriculture. The semiconductor industry has been on a tear lately due to the shortage, lifting ASML to elevated levels.</p>\n<p>ASML has benefited greatly from an increased emphasis on digitization among developed nations.</p>\n<p>The recent repurchase creates an asymmetric risk-reward opportunity.</p>\n<p>The valuation is quite high but the company's impressive growth prospects justify the premium.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASML":"阿斯麦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132829556","content_text":"ASML shares rose more than 2% to a record high.\n\nASML Holding is a Dutch multinational company specializing in developing, producing, and maintaining photolithography machines. ASML is a major supplier to the semiconductor industry. The firm offers chipmakers with hardware, software, and services for mass-producing microchips. ASML works to develop more affordable, more powerful, and more energy-efficient microchips. ASML contributes to ground-breaking science that solves some of humanity's most pressing issues, such as healthcare, energy use and conservation, mobility, and agriculture. The semiconductor industry has been on a tear lately due to the shortage, lifting ASML to elevated levels.\nASML has benefited greatly from an increased emphasis on digitization among developed nations.\nThe recent repurchase creates an asymmetric risk-reward opportunity.\nThe valuation is quite high but the company's impressive growth prospects justify the premium.","news_type":1,"symbols_score_info":{"ASML":0.9}},"isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375544486,"gmtCreate":1619371140645,"gmtModify":1704722924367,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"like and comment pls","listText":"like and comment pls","text":"like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/375544486","repostId":"1184404050","repostType":4,"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325771364,"gmtCreate":1615940795158,"gmtModify":1704788656713,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"themes":[],"htmlText":"pls like and comment","listText":"pls like and comment","text":"pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/325771364","repostId":"1150337731","repostType":4,"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}